Molecular targeted therapy for anticancer treatment

Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precis...

Full description

Saved in:
Bibliographic Details
Published inExperimental & molecular medicine Vol. 54; no. 10; pp. 1670 - 1694
Main Authors Min, Hye-Young, Lee, Ho-Young
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.10.2022
Springer Nature B.V
Subjects
631/67/1059/602
692/699/67/1059/602
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer therapies
Chemotherapy
Drug development
Drug resistance
Drug Resistance, Neoplasm
Humans
Medical Biochemistry
Molecular Medicine
Molecular Targeted Therapy
Monoclonal antibodies
Mutation
Neoplasms - drug therapy
Neoplasms - genetics
Precision Medicine
Review
Review Article
Signal transduction
Stem Cells
Therapeutic targets
Tumor cells
Online AccessGet full text

Cover

Abstract Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development. Cancer: A focused approach to therapy Molecular targeted therapies have transformed cancer treatment, enabling personalized treatment of tumors in which growth is being powered by specific mutations. In contrast to traditional chemotherapies, which are toxic to both healthy and tumor cells, these targeted agents are designed to specifically block the effects of particular signaling proteins whose activity is largely restricted to cancerous tissue. Hye-Young Min and Ho-Young Lee at Seoul National University, South Korea, briefly review the history of the development of these drugs, and outline the mechanisms by which different targeted therapies work and how the acquisition of new tumor mutations can confer drug resistance. They also examine recent progress in developing agents that target proteins that have previously proven challenging therapeutic targets, such as the well-known oncogene KRAS , and explore potential opportunities for future therapeutic development.
AbstractList Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development. Molecular targeted therapies have transformed cancer treatment, enabling personalized treatment of tumors in which growth is being powered by specific mutations. In contrast to traditional chemotherapies, which are toxic to both healthy and tumor cells, these targeted agents are designed to specifically block the effects of particular signaling proteins whose activity is largely restricted to cancerous tissue. Hye-Young Min and Ho-Young Lee at Seoul National University, South Korea, briefly review the history of the development of these drugs, and outline the mechanisms by which different targeted therapies work and how the acquisition of new tumor mutations can confer drug resistance. They also examine recent progress in developing agents that target proteins that have previously proven challenging therapeutic targets, such as the well-known oncogene KRAS , and explore potential opportunities for future therapeutic development.
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development.
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development.Cancer: A focused approach to therapyMolecular targeted therapies have transformed cancer treatment, enabling personalized treatment of tumors in which growth is being powered by specific mutations. In contrast to traditional chemotherapies, which are toxic to both healthy and tumor cells, these targeted agents are designed to specifically block the effects of particular signaling proteins whose activity is largely restricted to cancerous tissue. Hye-Young Min and Ho-Young Lee at Seoul National University, South Korea, briefly review the history of the development of these drugs, and outline the mechanisms by which different targeted therapies work and how the acquisition of new tumor mutations can confer drug resistance. They also examine recent progress in developing agents that target proteins that have previously proven challenging therapeutic targets, such as the well-known oncogene KRAS, and explore potential opportunities for future therapeutic development.
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development.Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development.
Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment. These approaches are now used clinically as first-line therapy for various types of human cancers. Compared to conventional chemotherapy, targeted therapeutic agents have efficient anticancer effects with fewer side effects. However, the emergence of drug resistance is a major drawback of molecular targeted therapy, and several strategies have been attempted to improve therapeutic efficacy by overcoming such resistance. Herein, we summarize current knowledge regarding several targeted therapeutic agents, including classification, a brief biology of target kinases, mechanisms of action, examples of clinically used targeted therapy, and perspectives for future development. Cancer: A focused approach to therapy Molecular targeted therapies have transformed cancer treatment, enabling personalized treatment of tumors in which growth is being powered by specific mutations. In contrast to traditional chemotherapies, which are toxic to both healthy and tumor cells, these targeted agents are designed to specifically block the effects of particular signaling proteins whose activity is largely restricted to cancerous tissue. Hye-Young Min and Ho-Young Lee at Seoul National University, South Korea, briefly review the history of the development of these drugs, and outline the mechanisms by which different targeted therapies work and how the acquisition of new tumor mutations can confer drug resistance. They also examine recent progress in developing agents that target proteins that have previously proven challenging therapeutic targets, such as the well-known oncogene KRAS , and explore potential opportunities for future therapeutic development.
Author Min, Hye-Young
Lee, Ho-Young
Author_xml – sequence: 1
  givenname: Hye-Young
  surname: Min
  fullname: Min, Hye-Young
  organization: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University
– sequence: 2
  givenname: Ho-Young
  orcidid: 0000-0001-7556-9312
  surname: Lee
  fullname: Lee, Ho-Young
  email: hylee135@snu.ac.kr
  organization: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36224343$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1LxDAQhoMofv8BD7LgxUs1maRJexFE_ALFi_eQptO10k3WJBX235t1_T54SmCed-adeXfIuvMOCTlg9IRRXp1GBqBkQQEKSispCr5GtoHWUEjB-PqP_xbZifGZUiiFEptki0sAwQXfJvzeD2jHwYRJMmGKCdtJesJg5otJ58PEuNRb4yzmekCTZujSHtnozBBx_-PdJY9Xl48XN8Xdw_XtxfldYUtBU5EHlC3taM2l7VRTQ8d5S6WsoGyRVUaYpoKmUXkHtFIZxhRQiRWKVqmm4bvkbNV2PjYzbG2eHMyg56GfmbDQ3vT6d8X1T3rqX3UtuWSizg2OPxoE_zJiTHrWR4vDYBz6MWpQIMpKAMiMHv1Bn_0YXN4uU5zVgvNSZOrwp6MvK5_nzACsABt8jAG7L4RRvcxMrzLTOTP9npleiqo_Itsnk3q_3Kof_pfylTTmOW6K4dv2P6o3OzeqNw
CitedBy_id crossref_primary_10_3390_ijms25105424
crossref_primary_10_3390_ijms25052649
crossref_primary_10_1016_j_phrs_2022_106552
crossref_primary_10_1016_j_lfs_2024_123178
crossref_primary_10_1016_j_tem_2023_08_018
crossref_primary_10_1080_10799893_2024_2411690
crossref_primary_10_3390_bioengineering11030264
crossref_primary_10_3390_cancers16244253
crossref_primary_10_1039_D4MD00881B
crossref_primary_10_1200_PO_24_00173
crossref_primary_10_1016_j_ijbiomac_2024_135992
crossref_primary_10_3390_targets2030011
crossref_primary_10_1007_s11030_024_10908_7
crossref_primary_10_3390_cells12162083
crossref_primary_10_1002_cbin_12275
crossref_primary_10_1016_j_ijbiomac_2025_141518
crossref_primary_10_3390_cells12222593
crossref_primary_10_3390_ijms24032796
crossref_primary_10_1002_1878_0261_13764
crossref_primary_10_1016_j_cis_2024_103356
crossref_primary_10_4254_wjh_v16_i10_1338
crossref_primary_10_3390_metabo14040229
crossref_primary_10_1016_j_oor_2024_100469
crossref_primary_10_1007_s11060_024_04763_7
crossref_primary_10_1007_s11427_024_2707_9
crossref_primary_10_1007_s12033_024_01189_4
crossref_primary_10_1016_j_prp_2024_155523
crossref_primary_10_1021_acs_chemrev_4c00745
crossref_primary_10_1016_j_biopha_2024_117705
crossref_primary_10_1186_s43556_024_00182_2
crossref_primary_10_3389_fphar_2024_1465055
crossref_primary_10_3390_ijms26052297
crossref_primary_10_26599_NR_2025_94907178
crossref_primary_10_1002_adma_202313955
crossref_primary_10_3390_cancers17061008
crossref_primary_10_1093_jjco_hyae117
crossref_primary_10_1016_j_cellsig_2024_111434
crossref_primary_10_1016_j_compbiomed_2024_108040
crossref_primary_10_7554_eLife_90532_3
crossref_primary_10_1158_1078_0432_CCR_23_0795
crossref_primary_10_59324_ejmhr_2024_2_5__03
crossref_primary_10_1007_s00403_024_03302_8
crossref_primary_10_1016_j_biopha_2023_115331
crossref_primary_10_1016_j_biomaterials_2023_122353
crossref_primary_10_3390_biomedicines12122659
crossref_primary_10_3390_ijms251910326
crossref_primary_10_1007_s00011_025_02011_w
crossref_primary_10_1038_s12276_023_01114_w
crossref_primary_10_1016_j_ijbiomac_2024_138211
crossref_primary_10_1021_acsomega_3c01195
crossref_primary_10_1016_j_jconrel_2024_09_029
crossref_primary_10_1016_j_ijpharm_2024_124004
crossref_primary_10_26787_nydha_2618_8783_2023_8_3_48_53
crossref_primary_10_1016_j_arabjc_2023_105423
crossref_primary_10_3390_cancers16020416
crossref_primary_10_1002_ptr_8407
crossref_primary_10_1016_j_jddst_2024_106556
crossref_primary_10_1002_anie_202416210
crossref_primary_10_12677_PI_2024_131001
crossref_primary_10_1016_j_biopsych_2024_12_004
crossref_primary_10_1016_j_rechem_2024_101350
crossref_primary_10_1016_j_tranon_2025_102353
crossref_primary_10_1016_j_jmgm_2025_109005
crossref_primary_10_3390_biomedicines11072086
crossref_primary_10_1186_s12943_023_01873_0
crossref_primary_10_3389_fmed_2024_1403466
crossref_primary_10_7554_eLife_90532
crossref_primary_10_1016_j_cca_2024_120028
crossref_primary_10_1016_j_clinimag_2025_110439
crossref_primary_10_1038_s41467_025_55904_z
crossref_primary_10_1016_j_jconrel_2024_12_004
crossref_primary_10_1021_acs_jproteome_3c00862
crossref_primary_10_1016_j_toxrep_2024_101833
crossref_primary_10_1186_s12964_024_01874_6
crossref_primary_10_1007_s00761_024_01663_3
crossref_primary_10_1016_j_jiec_2024_07_049
crossref_primary_10_3390_molecules29235672
crossref_primary_10_1016_j_cbi_2024_111344
crossref_primary_10_3390_ph18020169
crossref_primary_10_1038_s41420_024_01884_w
crossref_primary_10_1016_j_omtn_2025_102483
crossref_primary_10_1021_acs_molpharmaceut_4c00703
crossref_primary_10_1002_jbt_70197
crossref_primary_10_1002_ange_202416210
crossref_primary_10_1016_j_jclinepi_2025_111676
crossref_primary_10_1039_D3BM01994B
crossref_primary_10_3390_cancers17020165
crossref_primary_10_1016_j_compbiomed_2024_108066
crossref_primary_10_2147_PGPM_S431346
crossref_primary_10_12677_acm_2024_1451389
crossref_primary_10_3390_medicina60121914
crossref_primary_10_22551_2023_41_1004_10266
crossref_primary_10_1016_j_vacune_2024_02_011
crossref_primary_10_1213_ANE_0000000000007210
crossref_primary_10_1097_RLI_0000000000001096
crossref_primary_10_1002_ctm2_70078
crossref_primary_10_1039_D3QM00239J
crossref_primary_10_3389_fimmu_2024_1479483
crossref_primary_10_1002_mco2_70009
crossref_primary_10_47026_2413_4864_2023_3_50_57
crossref_primary_10_1016_j_taap_2024_117204
crossref_primary_10_3390_targets2040018
crossref_primary_10_1016_j_molstruc_2025_141576
crossref_primary_10_1021_acsmedchemlett_3c00212
crossref_primary_10_1016_j_jconrel_2024_05_040
crossref_primary_10_1016_j_humpath_2023_07_012
crossref_primary_10_1038_s41540_024_00379_9
crossref_primary_10_3390_ijms25158448
crossref_primary_10_3390_ijms24054385
crossref_primary_10_1016_j_bioorg_2024_107804
crossref_primary_10_1016_j_phrs_2024_107059
crossref_primary_10_1186_s13104_024_07016_y
crossref_primary_10_1016_j_rechem_2024_101490
crossref_primary_10_1016_j_clinthera_2024_08_020
crossref_primary_10_1016_j_sajb_2023_09_049
crossref_primary_10_1111_1759_7714_15495
crossref_primary_10_3390_ph16111591
crossref_primary_10_1007_s12032_024_02501_7
crossref_primary_10_1016_j_bioorg_2025_108189
crossref_primary_10_1016_j_cpet_2024_03_006
crossref_primary_10_1021_acs_jmedchem_4c00967
crossref_primary_10_3390_cancers16244281
crossref_primary_10_1021_acssynbio_4c00483
crossref_primary_10_1007_s00109_023_02300_z
crossref_primary_10_1007_s00761_025_01712_5
crossref_primary_10_1016_j_ijbiomac_2025_141605
crossref_primary_10_3389_fonc_2024_1413255
crossref_primary_10_1007_s11696_024_03648_3
crossref_primary_10_1055_a_2521_4104
crossref_primary_10_3892_or_2024_8821
crossref_primary_10_37349_etat_2025_1002286
crossref_primary_10_1142_S2737416524500145
crossref_primary_10_15212_AMM_2023_0008
crossref_primary_10_3923_biotech_2023_18_27
crossref_primary_10_7759_cureus_61244
crossref_primary_10_3390_ijms241814336
crossref_primary_10_1016_j_esmoop_2024_104089
crossref_primary_10_3390_biomedinformatics4030101
crossref_primary_10_3390_biomedicines12040751
crossref_primary_10_2174_0113892002312369240703102215
crossref_primary_10_1016_j_compbiomed_2024_108484
crossref_primary_10_1007_s12282_024_01625_y
crossref_primary_10_3390_ijms25169032
crossref_primary_10_1016_j_drudis_2024_104059
crossref_primary_10_1134_S1070363224110185
crossref_primary_10_56083_RCV3N11_218
crossref_primary_10_3892_or_2023_8613
crossref_primary_10_1007_s44178_025_00149_5
crossref_primary_10_1007_s13205_024_04189_y
crossref_primary_10_32635_2176_9745_RBC_2024v70n1_4628
crossref_primary_10_3390_cancers15225424
crossref_primary_10_15583_jpchrom_2023_010
crossref_primary_10_1007_s12032_024_02580_6
crossref_primary_10_1016_j_jlb_2024_100281
crossref_primary_10_1002_slct_202402092
crossref_primary_10_1039_D4MA00496E
crossref_primary_10_1007_s10120_024_01537_y
crossref_primary_10_1158_0008_5472_CAN_23_3508
crossref_primary_10_3390_ani15030444
crossref_primary_10_3390_children10101656
crossref_primary_10_4254_wjh_v16_i10_1158
crossref_primary_10_1038_s12276_023_01051_8
crossref_primary_10_1038_s41392_023_01522_4
crossref_primary_10_3390_cancers16050984
crossref_primary_10_3390_jcm13144189
crossref_primary_10_1016_j_ccr_2024_216207
crossref_primary_10_1016_j_cvsm_2023_12_006
crossref_primary_10_1016_j_prp_2024_155424
crossref_primary_10_1364_BOE_557218
crossref_primary_10_1016_j_vacun_2023_10_005
crossref_primary_10_1021_acs_inorgchem_3c03216
crossref_primary_10_1016_j_jconrel_2024_05_007
crossref_primary_10_3390_cancers16132478
crossref_primary_10_1016_j_oor_2025_100724
crossref_primary_10_3389_fphar_2024_1461478
crossref_primary_10_1016_j_canlet_2024_217108
crossref_primary_10_3390_pharmaceutics16091181
crossref_primary_10_1016_j_bioorg_2024_107891
crossref_primary_10_1039_D4DT01571A
crossref_primary_10_1016_j_bbrc_2025_151370
crossref_primary_10_3390_cells13242053
crossref_primary_10_1002_masy_202400075
crossref_primary_10_1016_j_jconrel_2024_08_035
crossref_primary_10_31083_j_fbl2905168
crossref_primary_10_3389_fphar_2024_1393112
crossref_primary_10_1039_D4MD00003J
crossref_primary_10_1016_j_bioorg_2024_107778
crossref_primary_10_1021_acs_inorgchem_3c04382
crossref_primary_10_1016_j_ejmech_2025_117278
crossref_primary_10_1038_s41388_024_03070_9
crossref_primary_10_1007_s11094_024_03092_3
crossref_primary_10_1039_D4OB00600C
Cites_doi 10.1039/C7MD00030H
10.1016/j.ejphar.2018.07.034
10.1158/1078-0432.CCR-12-2087
10.1182/blood-2011-09-379214
10.1038/nrc.2015.21
10.1038/sj.onc.1208160
10.1186/s12935-020-01614-z
10.1038/leu.2009.111
10.1126/science.aan4236
10.1080/17474086.2021.1969911
10.1016/j.ctrv.2014.05.003
10.3389/fcell.2021.637675
10.1007/s40265-015-0386-x
10.1186/s13045-020-00949-4
10.1007/s11899-021-00619-3
10.3389/fmmed.2021.749283
10.1146/annurev-cancerbio-030419-033533
10.3390/cancers10100342
10.1007/s40265-013-0111-6
10.1158/1538-7445.AM2022-5350
10.1038/nrclinonc.2010.97
10.1158/0008-5472.CAN-19-3682
10.1021/acs.jmedchem.1c01688
10.1158/1078-0432.CCR-21-4498
10.1038/nrm1498
10.1186/s12943-018-0776-2
10.1016/j.cell.2017.02.004
10.1056/NEJMoa1902328
10.1634/theoncologist.2009-0009
10.1186/s13045-015-0194-5
10.1007/s40265-021-01574-2
10.1093/jjco/hyaa192
10.1186/s12943-019-0954-x
10.1021/ml500394m
10.1007/s40265-015-0533-4
10.4161/onci.21940
10.1080/13814788.2020.1846713
10.1158/1078-0432.CCR-08-1018
10.1038/s41571-018-0081-4
10.3389/fonc.2019.00800
10.3390/cancers14112641
10.1016/j.ccell.2020.03.006
10.3389/fonc.2021.672500
10.1186/1476-4598-9-139
10.4062/biomolther.2021.047
10.1038/s41421-021-00368-w
10.1093/jnci/djn389
10.21873/anticanres.13476
10.1016/j.canlet.2016.11.008
10.1038/ni0903-815
10.1016/j.jtho.2018.01.009
10.1016/j.cell.2010.06.011
10.1038/s41375-020-01072-6
10.1016/j.tips.2011.11.002
10.1007/s40265-021-01533-x
10.3390/cancers9050052
10.1158/2326-6066.CIR-18-0193
10.18632/oncotarget.2925
10.1158/2159-8290.CD-21-0379
10.1016/j.trecan.2021.07.003
10.3324/haematol.2013.096776
10.1186/s13045-022-01299-z
10.1038/s41416-021-01319-8
10.18632/oncotarget.14012
10.1038/s41571-022-00639-9
10.1038/sj.onc.1210381
10.1586/14737140.9.3.331
10.1186/s12943-018-0804-2
10.3389/fcell.2020.564601
10.1038/nrc2505
10.1158/1078-0432.CCR-07-2114
10.1158/1078-0432.CCR-18-3003
10.1007/s40264-018-0772-x
10.1038/nrd2792
10.1016/S1470-2045(11)70335-7
10.1242/dev.091744
10.1126/scitranslmed.3002003
10.1002/anie.201307387
10.1159/000443526
10.1159/000071078
10.1158/0008-5472.CAN-06-1199
10.1126/scisignal.3139re6
10.21037/jtd.2017.06.08
10.1038/modpathol.2009.43
10.1038/s41577-020-0306-5
10.1186/s12943-018-0779-z
10.1158/0008-5472.CAN-06-4443
10.2147/DDDT.S31442
10.1186/s13045-021-01040-2
10.3390/cancers13071538
10.1158/1078-0432.CCR-12-0284
10.1152/physrev.00029.2018
10.1038/s41523-021-00265-1
10.1159/000371821
10.1177/2040620717719851
10.1158/1078-0432.CCR-15-0407
10.3390/antib9030034
10.3389/fphar.2020.580251
10.1093/annonc/mdz131
10.1038/s41573-020-0068-6
10.3390/ph8010001
10.1186/s12943-021-01317-7
10.1016/j.critrevonc.2016.01.024
10.1186/1478-811X-11-97
10.1200/JCO.21.02742
10.1038/nrc2088
10.1038/s41419-020-02998-6
10.1158/2159-8290.CD-15-0285
10.1186/s12943-018-0782-4
10.1158/1078-0432.CCR-09-1070
10.3390/cancers12102801
10.1038/s41392-021-00572-w
10.1182/blood-2016-02-702761
10.1038/35067005
10.1158/2159-8290.CD-14-0337
10.1200/JCO.21.01494
10.1158/1078-0432.CCR-21-0465
10.1126/science.aam7344
10.1038/sj.bjc.6603170
10.2147/OTT.S189391
10.1093/bmb/ldx045
10.1016/j.ccr.2009.11.022
10.1186/s13045-019-0718-5
10.1080/23808993.2021.1909420
10.1677/erc.1.01221
10.1038/s41586-021-04065-2
10.1016/j.ccell.2019.12.013
10.1093/gastro/goaa026
10.1038/s41586-020-2541-0
10.1002/cam4.4041
10.1016/j.ccell.2020.03.007
10.1038/s41540-019-0113-4
10.3322/caac.21660
10.1016/j.cell.2011.02.013
10.5581/1516-8484.20110034
10.1177/1756283X15592586
10.1038/sj.leu.2403355
10.1016/j.phrs.2015.10.021
10.1038/s41571-018-0113-0
10.1038/nature04186
10.1016/j.phrs.2013.11.002
10.1016/j.mpmed.2015.10.012
10.1038/s41392-020-00313-5
10.1038/leu.2010.73
10.3390/molecules27030819
10.1158/1078-0432.CCR-040005
10.1016/j.ctrv.2020.102017
10.1016/j.pharmthera.2020.107522
10.1634/theoncologist.12-12-1443
10.1016/j.celrep.2018.05.082
10.1186/s13045-018-0624-2
10.1038/s41416-019-0573-8
10.1634/theoncologist.10-3-176
10.1038/s41573-021-00371-6
10.2147/CMAR.S201024
10.1097/MD.0000000000016785
10.1158/1078-0432.CCR-06-2328
10.1016/j.mpmed.2015.10.014
10.1158/1078-0432.CCR-08-1306
10.1016/j.bbapap.2012.10.015
10.1158/1535-7163.MCT-19-0873
10.1002/anie.201914525
10.1182/blood.2019876821
10.1007/BF02976989
10.1373/clinchem.2015.247882
10.1007/s40265-018-0884-8
10.34133/2022/9816939
10.1158/1078-0432.CCR-16-0569
10.1021/acs.jmedchem.8b01040
10.1158/0008-5472.CAN-15-0989
10.1038/s41416-021-01344-7
10.1038/s41375-021-01123-6
10.1200/JOP.19.00357
10.1097/JTO.0b013e3181f1c8de
10.1158/1535-7163.MCT-11-0697
10.1038/s41392-020-00222-7
10.7150/ijbs.6087
10.1038/nrc2403
10.1089/cbr.1999.14.5
10.1002/jcph.1028
10.3389/fphar.2021.645864
10.1158/1078-0432.CCR-18-0968
10.1016/j.mpmed.2015.10.009
10.1038/nrc.2016.138
10.1158/2159-8290.CD-18-1321
10.1016/j.ctrv.2020.102137
10.1038/onc.2014.257
10.1038/onc.2008.109
10.1158/1078-0432.CCR-05-1554
10.1111/bcp.14889
10.2217/fon-2020-1244
10.1016/j.flm.2017.06.001
10.1186/s12943-018-0810-4
10.3390/ijms19113491
10.3390/cancers13122968
10.1182/hematology.2020000118
10.1186/s13058-018-1050-7
10.1177/1758835921992976
10.1097/JTO.0b013e3181913c9f
10.1007/s40265-019-01115-y
10.1177/1758834014566428
10.1016/j.bcp.2011.12.024
10.1056/NEJMoa2105281
10.3390/cells10051255
10.1016/j.eclinm.2020.100487
10.1016/j.biopha.2022.113064
10.1016/j.phrs.2019.104567
10.1188/05.CJON.332-338
10.1038/s41574-021-00470-9
10.1056/NEJMoa2204619
10.1074/jbc.RA118.003036
10.1002/med.21774
10.1158/1078-0432.CCR-05-0790
10.1038/nrc3563
10.3390/cells7110212
10.1634/theoncologist.2010-0035
10.1093/annonc/mdx219
10.1016/j.ejca.2008.09.013
10.1038/s41388-020-01539-x
10.1038/s41375-020-0954-2
10.1101/gad.1653708
10.1038/s41408-022-00687-5
10.1007/s00134-019-05650-w
10.1111/cas.14609
10.2165/11205090-000000000-00000
10.1186/s40425-019-0643-8
10.1111/bph.12344
10.1097/CCO.0000000000000426
10.1038/s41573-021-00195-4
10.3390/cancers12061448
10.1158/1078-0432.CCR-14-2791
10.1038/nrc.2017.8
10.1016/j.bbcan.2021.188666
10.4143/crt.2022.078
10.1016/j.trecan.2019.12.007
10.3390/cells8050394
10.1016/j.mpmed.2015.10.007
10.1016/bs.acr.2020.04.009
10.3389/fonc.2022.755053
10.1016/j.annonc.2020.08.1610
10.1007/s40265-018-1028-x
10.1136/gutjnl-2021-326264
10.1038/nature12796
10.1093/jncimonographs/lgz008
10.1007/978-3-030-73440-4_4
10.4161/cbt.5.4.2666
10.1200/EDBK_159167
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1038/s12276-022-00864-3
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
Publicly Available Content Database
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 2092-6413
EndPage 1694
ExternalDocumentID PMC9636149
36224343
10_1038_s12276_022_00864_3
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: National Research Foundation of Korea (NRF)
  grantid: NRF-2016R1A3B1908631
  funderid: https://doi.org/10.13039/501100003725
– fundername: ;
  grantid: NRF-2016R1A3B1908631
GroupedDBID ---
0R~
29G
2WC
3V.
5-W
53G
5GY
7X7
87B
88E
8FE
8FH
8FI
8FJ
8JR
9ZL
AAJSJ
ABUWG
ACGFO
ACGFS
ACPRK
ACSMW
ACYCR
ADBBV
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
C1A
C6C
CCPQU
DIK
DU5
E3Z
EBLON
EBS
EF.
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
LK8
M1P
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
TR2
UKHRP
W2D
XSB
AASML
AAYXX
CITATION
OVT
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
8FK
AARCD
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c540t-4345d0f0936cf7b92f33d066825de18a4ab82bb7276ec67a117206e8e4d77bb3
IEDL.DBID 7X7
ISSN 2092-6413
1226-3613
IngestDate Thu Aug 21 18:39:12 EDT 2025
Sun Aug 24 04:11:26 EDT 2025
Wed Aug 13 06:43:28 EDT 2025
Mon Jul 21 06:01:58 EDT 2025
Tue Jul 01 04:10:31 EDT 2025
Thu Apr 24 22:57:19 EDT 2025
Fri Feb 21 02:40:08 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c540t-4345d0f0936cf7b92f33d066825de18a4ab82bb7276ec67a117206e8e4d77bb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0001-7556-9312
OpenAccessLink https://www.proquest.com/docview/2731943354?pq-origsite=%requestingapplication%
PMID 36224343
PQID 2731943354
PQPubID 2041975
PageCount 25
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9636149
proquest_miscellaneous_2724584226
proquest_journals_2731943354
pubmed_primary_36224343
crossref_primary_10_1038_s12276_022_00864_3
crossref_citationtrail_10_1038_s12276_022_00864_3
springer_journals_10_1038_s12276_022_00864_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-10-01
PublicationDateYYYYMMDD 2022-10-01
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: Seoul
PublicationTitle Experimental & molecular medicine
PublicationTitleAbbrev Exp Mol Med
PublicationTitleAlternate Exp Mol Med
PublicationYear 2022
Publisher Nature Publishing Group UK
Springer Nature B.V
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
References Reungwetwattana, Rohatgi, Mok, Prabhash (CR201) 2021; 6
Xie (CR126) 2020; 5
Greuber, Smith-Pearson, Wang, Pendergast (CR135) 2013; 13
Shah, Shah (CR73) 2019; 42
Hou (CR39) 2022; 12
Naito, Shiraishi, Fujiwara (CR101) 2021; 51
Fallahi (CR221) 2015; 9
Ha, Choi, Kwon, Park, Shin (CR231) 2019; 98
Mao (CR186) 2022; 8
Colicelli (CR136) 2010; 3
Cho, Esmail, Raza, Dacha, Abdelrahim (CR91) 2022; 14
Charlton, Spicer (CR9) 2016; 44
Howie (CR210) 2019; 25
Kobayashi (CR67) 2018; 13
Martellucci (CR150) 2020; 12
Jones, Iljin, Dumont, Alitalo (CR129) 2001; 2
Cerchione (CR215) 2021; 14
Awad (CR247) 2021; 384
Prior, Hood, Hartley (CR156) 2020; 80
Cheah, Fowler (CR172) 2016; 128
Shirley (CR200) 2018; 78
Marusyk, Janiszewska, Polyak (CR41) 2020; 37
Cross (CR70) 2014; 4
Liu, Kurzrock (CR52) 2014; 40
Kim (CR78) 2022; 82
Lin, Gainor (CR228) 2021; 124
Julia, Salles (CR252) 2021; 17
Hanahan, Weinberg (CR22) 2011; 144
El-Kenawi, El-Remessy (CR117) 2013; 170
Schlam, Swain (CR211) 2021; 7
Goodman (CR218) 2007; 13
Bekes, Langley, Crews (CR180) 2022; 21
Saini, Twelves (CR4) 2021; 125
Ernani, Stinchcombe (CR100) 2019; 15
Cooper, Sequist, Lin (CR203) 2022; 19
Chauhan, Cheson (CR171) 2021; 13
Qin (CR220) 2019; 12
Lipsky, Lamanna (CR235) 2020; 2020
Sung (CR1) 2021; 71
Assoun, Lemiale, Azoulay (CR53) 2019; 45
Usborne, Mullard (CR5) 2017; 125
Zhao (CR208) 2017; 8
Habeeb (CR15) 2016; 62
Babina, Turner (CR124) 2017; 17
CR255
Bondarev (CR250) 2021; 87
Tan, Putoczki, Stylli, Luwor (CR145) 2019; 12
Duggirala, Lee, Lee (CR74) 2022; 30
Zahavi, Weiner (CR20) 2020; 9
Turke (CR104) 2010; 17
Kohlmann (CR110) 2010; 24
Dillman (CR18) 1999; 14
Li (CR65) 2008; 27
Dhillon (CR72) 2021; 81
Joosten (CR219) 2015; 1855
Abraham, Staffurth (CR11) 2016; 44
Jiang (CR226) 2021; 10
Meador, Hata (CR43) 2020; 210
Qin (CR48) 2020; 5
Pirker (CR57) 2010; 5
CR149
Rose, Burgess, O’Byrne, Richard, Bolderson (CR178) 2020; 8
Conchon, Freitas, Rego, Braga Junior (CR233) 2011; 33
Liang (CR127) 2013; 9
Boekhout, Beijnen, Schellens (CR209) 2011; 16
Valent (CR16) 2016; 8
Lau, Batra, Mok, Loong (CR66) 2019; 79
Li (CR88) 2020; 8
Pal Singh, Dammeijer, Hendriks (CR152) 2018; 17
Leonetti (CR75) 2019; 121
Hume, MacDonald (CR130) 2012; 119
Lord, Ashworth (CR177) 2016; 16
Armaghani, Han (CR243) 2020; 12
Golding, Luu, Jones, Viloria-Petit (CR96) 2018; 17
Blair (CR164) 2021; 81
Okamoto (CR28) 2015; 6
Nami, Maadi, Wang (CR90) 2018; 10
Ni (CR46) 2021; 9
Hortobagyi (CR174) 2018; 20
Lietman, Johnson, McCormick, Lindsay (CR183) 2022; 42
Wang, Yao, Huang (CR162) 2017; 8
Johnson (CR64) 2005; 11
Bauer, George, von Mehren, Heinrich (CR222) 2021; 11
Zhang (CR102) 2016; 22
Ke, Shen (CR2) 2017; 1
Sudhan (CR212) 2020; 37
Yamaoka, Kusumoto, Ando, Ohba, Ohmori (CR134) 2018; 19
Kommalapati, Tella, Borad, Javle, Mahipal (CR224) 2021; 13
Young, Smyth, Chau (CR230) 2015; 8
Wheeler, Iida, Dunn (CR147) 2009; 14
Yuan, Dong, Yap, Hu (CR167) 2020; 13
van der Wekken (CR196) 2016; 100
Dungo, Keating (CR198) 2013; 73
Koelblinger, Thuerigen, Dummer (CR168) 2018; 30
Kadosh (CR193) 2020; 586
Seavey, Dobrzanski (CR153) 2012; 83
Kun, Tsang, Ng, Gershenson, Wong (CR242) 2021; 92
Jemal (CR3) 2008; 100
Webb (CR93) 2009; 9
Kaminskas, Farrell, Wang, Sridhara, Pazdur (CR248) 2005; 10
Lim (CR184) 2014; 53
Friedman (CR217) 2022; 1877
Lord, Ashworth (CR175) 2017; 355
Roskoski (CR133) 2020; 151
Giles, O’Dwyer, Swords (CR138) 2009; 23
Keshava (CR189) 2019; 5
Ostrem, Peters, Sos, Wells, Shokat (CR182) 2013; 503
Rusnak, Gilmer (CR82) 2011; 10
Cohen, Cross, Jänne (CR23) 2021; 20
Kim (CR249) 2022; 28
Ayeni (CR37) 2019; 7
Luo, Peng, Ma (CR190) 2022; 2022
Sanchez, Wang, Cohen (CR240) 2018; 78
Schoepfer (CR143) 2018; 61
Ting, Lau, Yu (CR191) 2022; 71
Li (CR245) 2020; 11
Kersh (CR30) 2018; 58
Yang, Hand, Livasy, Cance, Craven (CR132) 2003; 24
Thein, Velcheti, Mooers, Wu, Subbiah (CR227) 2021; 7
Widakowich, de Castro, de Azambuja, Dinh, Awada (CR50) 2007; 12
Zou (CR97) 2007; 67
Lee, Tan, Oon (CR14) 2018; 834
Vogel, Jennifer (CR204) 2016; 7
Peeters, Karthaus, Rivera, Terwey, Douillard (CR206) 2015; 75
Estupinan (CR236) 2021; 35
Yue, Chen, He (CR256) 2020; 20
Colomer (CR17) 2020; 25
Zhang, Nagasaka (CR163) 2021; 12
Lu, Smaill, Ding (CR27) 2020; 59
Li, Chen, Li, Liu, Ma (CR29) 2021; 20
Cho, Lee (CR161) 2002; 25
Laetsch, Hong (CR107) 2021; 27
Parsons, Parsons (CR146) 2004; 23
Fabbrocini, Panariello, Caro, Cacciapuoti (CR51) 2015; 1
Chow, Lie, Toi (CR86) 2020; 147
Hughes (CR144) 2019; 381
Merin, Kelly (CR254) 2014; 8
Heldin (CR114) 2013; 11
Rossari, Minutolo, Orciuolo (CR137) 2018; 11
Pilie, Gay, Byers, O’Connor, Yap (CR176) 2019; 25
Cocco, Scaltriti, Drilon (CR106) 2018; 15
Hsu (CR34) 2010; 9
Janne (CR165) 2022; 387
Pacheco (CR81) 2021; 11
Hochhaus (CR141) 2017; 28
Thomas, Weihua (CR58) 2019; 9
McCutcheon, Giaccone (CR187) 2015; 21
Turner, Reis-Filho (CR42) 2012; 13
Chen, Chen, He (CR112) 2013; 1834
Perl (CR109) 2019; 134
Liu (CR170) 2020; 11
Du, Lovly (CR24) 2018; 17
Wellbrock, Karasarides, Marais (CR166) 2004; 5
Gopalakrishnan (CR194) 2018; 359
Donia (CR36) 2012; 1
Liang, Brekken, Hyder (CR119) 2006; 13
Zhang, Yu (CR148) 2012; 33
Desikan (CR216) 2022; 12
Keating (CR89) 2010; 70
CR205
Roskoski (CR54) 2014; 79
Bhullar (CR21) 2018; 17
Andrae, Gallini, Betsholtz (CR113) 2008; 22
Kaplan (CR122) 2005; 438
Della Corte (CR92) 2018; 17
Zhong (CR8) 2021; 6
Joly, Hudrisier (CR31) 2003; 4
Puttini (CR140) 2006; 66
Waldman, Fritz, Lenardo (CR12) 2020; 20
Soares (CR131) 2009; 22
Fantin, Richon (CR251) 2007; 13
Recondo, Facchinetti, Olaussen, Besse, Friboulet (CR213) 2018; 15
Galizia (CR87) 2007; 26
Hong, Zhang, Heymach, Le (CR99) 2021; 13
Amelia, Kartasasmita, Ohwada, Tjahjono (CR62) 2022; 27
Katayama, Lovly, Shaw (CR95) 2015; 21
Xie, Paradise, Ma, Fernandez-Zapico (CR257) 2019; 8
Yaeger, Corcoran (CR157) 2019; 9
Ellis, Hicklin (CR38) 2009; 15
Lind (CR6) 2016; 44
Scaltriti, Baselga (CR55) 2006; 12
Beenken, Mohammadi (CR123) 2009; 8
Ha (CR61) 2015; 6
Kim (CR234) 2014; 99
Rebecca, Herlyn (CR40) 2020; 4
Kong (CR120) 2021; 40
Crook (CR111) 2021; 1
Wright, Vasilevski, Serra, Rodon, Eichhorn (CR244) 2021; 13
Guo (CR59) 2015; 75
Royce (CR246) 2022; 40
Eskazan, Keskin (CR142) 2017; 8
Peters (CR10) 2019; 39
Cohen (CR19) 2002; 8
Keefe, Bateman (CR13) 2019; 2019
Nagano, Tachihara, Nishimura (CR195) 2018; 7
Greig (CR202) 2016; 76
Shaw (CR98) 2019; 30
Kazi, Ronnstrand (CR108) 2019; 99
Zhao (CR238) 2021; 599
Li (CR44) 2022; 150
Zhao (CR121) 2015; 34
Matlung (CR33) 2018; 23
Garcia (CR229) 2020; 86
Proietti (CR239) 2020; 12
Kulukian (CR85) 2020; 19
Quintas-Cardama, Verstovsek (CR155) 2013; 19
Roger (CR49) 2020; 26
Thomas (CR207) 2005; 9
Giaccone (CR63) 2004; 10
Harper, Bates (CR116) 2008; 8
Otto, Sicinski (CR160) 2017; 17
Moore, Rosenberg, McCormick, Malek (CR181) 2020; 19
Liu, Duan, Zhang (CR47) 2021; 12
Saxton, Sabatini (CR169) 2017; 168
Rivera-Concepcion, Uprety, Adjei (CR79) 2022; 54
Ramirez-Labrada (CR192) 2020; 6
Wen, Wang, Shi, Qian, Liu (CR151) 2021; 35
Santarpia (CR71) 2017; 8
Eder, Vande Woude, Boerner, LoRusso (CR103) 2009; 15
Miyake, Karasuyama (CR32) 2021; 10
Suda, Onozato, Yatabe, Mitsudomi (CR69) 2009; 4
Wheeler, Dunn, Harari (CR45) 2010; 7
CR84
Lim, Kaldis (CR159) 2013; 140
Tsang, Sadeghi, Finn (CR83) 2011; 3
Yue (CR225) 2021; 14
Zhang (CR199) 2017; 9
Welsh, Corrie (CR241) 2015; 7
Lee, Daver, Kantarjian, Verstovsek, Ravandi (CR154) 2013; 19
Sequist (CR197) 2011; 3
Frampton (CR105) 2015; 5
Lizotte (CR35) 2018; 6
Scavelli, Vacca, Di Pietro, Dammacco, Ribatti (CR118) 2004; 18
Wang (CR185) 2022; 65
Lemmon, Schlessinger (CR25) 2010; 141
Udagawa, Zembutsu (CR188) 2020; 111
Meng, Liang, Zhao, Luo (CR179) 2021; 41
Sharma, Bell, Settleman, Haber (CR68) 2007; 7
Wee, Wang (CR60) 2017; 9
Braun, Eide, Druker (CR232) 2020; 37
McMurry, Fletcher, Traer (CR253) 2021; 16
Wang, Song, Liu (CR76) 2017; 385
Salvatore, Santoro, Schlumberger (CR128) 2021; 17
Jones (CR7) 2016; 44
Talpaz, Kiladjian (CR237) 2021; 35
Kohler, Janne (CR80) 2021; 39
Fujino (CR214) 2022; 15
Lu (CR173) 2015; 8
Regeenes (CR125) 2018; 293
Ellis, Hicklin (CR115) 2008; 8
Weisberg (CR139) 2006; 94
Cowey (CR223) 2013; 7
Dean-Colomb, Esteva (CR56) 2008; 44
Schalm (CR77) 2020; 31
Takeuchi (CR94) 2008; 14
Roskoski (CR26) 2016; 103
Yang (CR158) 2019; 18
DR Sudhan (864_CR212) 2020; 37
FH Tan (864_CR145) 2019; 12
SM Cho (864_CR91) 2022; 14
S Yue (864_CR225) 2021; 14
P Koelblinger (864_CR168) 2018; 30
JN Sanchez (864_CR240) 2018; 78
X Li (864_CR44) 2022; 150
PA Janne (864_CR165) 2022; 387
C Wellbrock (864_CR166) 2004; 5
C Widakowich (864_CR50) 2007; 12
Y Zhang (864_CR199) 2017; 9
AG Ramirez-Labrada (864_CR192) 2020; 6
GM Frampton (864_CR105) 2015; 5
DL Wheeler (864_CR147) 2009; 14
S Liu (864_CR52) 2014; 40
X Yue (864_CR256) 2020; 20
AD Waldman (864_CR12) 2020; 20
CD Lietman (864_CR183) 2022; 42
C Scavelli (864_CR118) 2004; 18
M Shirley (864_CR200) 2018; 78
864_CR149
AB Turke (864_CR104) 2010; 17
LM Ellis (864_CR115) 2008; 8
RR Shah (864_CR73) 2019; 42
M Santarpia (864_CR71) 2017; 8
A Jemal (864_CR3) 2008; 100
J Kohler (864_CR80) 2021; 39
D Ha (864_CR231) 2019; 98
R Roskoski Jr. (864_CR54) 2014; 79
SY Ha (864_CR61) 2015; 6
RA Saxton (864_CR169) 2017; 168
SJ Harper (864_CR116) 2008; 8
M Thomas (864_CR207) 2005; 9
J Hou (864_CR39) 2022; 12
SCE Wright (864_CR244) 2021; 13
T Nagano (864_CR195) 2018; 7
DA Cross (864_CR70) 2014; 4
Y Ni (864_CR46) 2021; 9
A Kulukian (864_CR85) 2020; 19
N Jones (864_CR129) 2001; 2
L Zhong (864_CR8) 2021; 6
NW-A Habeeb (864_CR15) 2016; 62
IS Babina (864_CR124) 2017; 17
S Pal Singh (864_CR152) 2018; 17
H Xie (864_CR257) 2019; 8
TR Webb (864_CR93) 2009; 9
S Bauer (864_CR222) 2021; 11
E Kaminskas (864_CR248) 2005; 10
JP Eder (864_CR103) 2009; 15
K Takeuchi (864_CR94) 2008; 14
I Schlam (864_CR211) 2021; 7
GM Keating (864_CR89) 2010; 70
LM Ellis (864_CR38) 2009; 15
LV Sequist (864_CR197) 2011; 3
R Liu (864_CR170) 2020; 11
JM Ostrem (864_CR182) 2013; 503
N Kim (864_CR249) 2022; 28
J Wang (864_CR162) 2017; 8
Y Xie (864_CR126) 2020; 5
F Meng (864_CR179) 2021; 41
NM Merin (864_CR254) 2014; 8
DA Hume (864_CR130) 2012; 119
TP Hughes (864_CR144) 2019; 381
X Wang (864_CR185) 2022; 65
W Dean-Colomb (864_CR56) 2008; 44
JJ Lin (864_CR228) 2021; 124
SCM Lau (864_CR66) 2019; 79
PH Chen (864_CR112) 2013; 1834
S Qin (864_CR48) 2020; 5
MH Cohen (864_CR19) 2002; 8
TW Laetsch (864_CR107) 2021; 27
T Yamaoka (864_CR134) 2018; 19
YT Lee (864_CR14) 2018; 834
SM Lim (864_CR184) 2014; 53
HL Matlung (864_CR33) 2018; 23
L Hong (864_CR99) 2021; 13
R Friedman (864_CR217) 2022; 1877
AE Eskazan (864_CR142) 2017; 8
G Galizia (864_CR87) 2007; 26
NC Turner (864_CR42) 2012; 13
D Zhao (864_CR121) 2015; 34
R Thomas (864_CR58) 2019; 9
JN McCutcheon (864_CR187) 2015; 21
AJ van der Wekken (864_CR196) 2016; 100
KB Duggirala (864_CR74) 2022; 30
RY Tsang (864_CR83) 2011; 3
KZ Thein (864_CR227) 2021; 7
J Abraham (864_CR11) 2016; 44
P Valent (864_CR16) 2016; 8
C Udagawa (864_CR188) 2020; 111
V Ernani (864_CR100) 2019; 15
T Otto (864_CR160) 2017; 17
J Andrae (864_CR113) 2008; 22
H McMurry (864_CR253) 2021; 16
M Scaltriti (864_CR55) 2006; 12
R Roskoski Jr. (864_CR133) 2020; 151
A Leonetti (864_CR75) 2019; 121
G Recondo (864_CR213) 2018; 15
J Schoepfer (864_CR143) 2018; 61
AR Moore (864_CR181) 2020; 19
E Kadosh (864_CR193) 2020; 586
864_CR84
A Beenken (864_CR123) 2009; 8
HA Blair (864_CR164) 2021; 81
Z Du (864_CR24) 2018; 17
CM Usborne (864_CR5) 2017; 125
AH Boekhout (864_CR209) 2011; 16
B Nami (864_CR90) 2018; 10
HY Estupinan (864_CR236) 2021; 35
M Donia (864_CR36) 2012; 1
J Yuan (864_CR167) 2020; 13
R Jones (864_CR7) 2016; 44
R Pirker (864_CR57) 2010; 5
Z Li (864_CR245) 2020; 11
CY Cheah (864_CR172) 2016; 128
R Katayama (864_CR95) 2015; 21
CB Meador (864_CR43) 2020; 210
A Hochhaus (864_CR141) 2017; 28
PG Pilie (864_CR176) 2019; 25
KS Saini (864_CR4) 2021; 125
D Li (864_CR65) 2008; 27
AE El-Kenawi (864_CR117) 2013; 170
A Kohlmann (864_CR110) 2010; 24
S Dhillon (864_CR72) 2021; 81
B Zhao (864_CR208) 2017; 8
RN Kaplan (864_CR122) 2005; 438
E Kun (864_CR242) 2021; 92
K Suda (864_CR69) 2009; 4
A Marusyk (864_CR41) 2020; 37
S Zhang (864_CR148) 2012; 33
J Rivera-Concepcion (864_CR79) 2022; 54
D Zahavi (864_CR20) 2020; 9
HJ Lee (864_CR154) 2013; 19
LJ Howie (864_CR210) 2019; 25
AE Perl (864_CR109) 2019; 134
NL Ting (864_CR191) 2022; 71
J Garcia (864_CR229) 2020; 86
B Golding (864_CR96) 2018; 17
P Cohen (864_CR23) 2021; 20
J Lu (864_CR173) 2015; 8
AD Bondarev (864_CR250) 2021; 87
GJ Peters (864_CR10) 2019; 39
JM Pacheco (864_CR81) 2021; 11
J Yang (864_CR158) 2019; 18
VW Rebecca (864_CR40) 2020; 4
WH Vogel (864_CR204) 2016; 7
EK Greuber (864_CR135) 2013; 13
K Okamoto (864_CR28) 2015; 6
DS Kim (864_CR78) 2022; 82
I Proietti (864_CR239) 2020; 12
DL Wheeler (864_CR45) 2010; 7
E Julia (864_CR252) 2021; 17
D Ayeni (864_CR37) 2019; 7
IA Prior (864_CR156) 2020; 80
MJ Soares (864_CR131) 2009; 22
RT Dungo (864_CR198) 2013; 73
C Cerchione (864_CR215) 2021; 14
J Colicelli (864_CR136) 2010; 3
VR Fantin (864_CR251) 2007; 13
SS Zhang (864_CR163) 2021; 12
Y Zhao (864_CR238) 2021; 599
Z Mao (864_CR186) 2022; 8
P Fallahi (864_CR221) 2015; 9
G Giaccone (864_CR63) 2004; 10
QH Li (864_CR88) 2020; 8
SS Schalm (864_CR77) 2020; 31
X Lu (864_CR27) 2020; 59
A Lipsky (864_CR235) 2020; 2020
D Salvatore (864_CR128) 2021; 17
S Zhang (864_CR102) 2016; 22
XH Yang (864_CR132) 2003; 24
MJ Lind (864_CR6) 2016; 44
T Wen (864_CR151) 2021; 35
D Kong (864_CR120) 2021; 40
T Fujino (864_CR214) 2022; 15
X Ke (864_CR2) 2017; 1
S Wang (864_CR76) 2017; 385
A Kommalapati (864_CR224) 2021; 13
KS Bhullar (864_CR21) 2018; 17
SL Greig (864_CR202) 2016; 76
M Peeters (864_CR206) 2015; 75
S Roger (864_CR49) 2020; 26
K Miyake (864_CR32) 2021; 10
FJ Giles (864_CR138) 2009; 23
T Crook (864_CR111) 2021; 1
E Weisberg (864_CR139) 2006; 94
864_CR205
S Martellucci (864_CR150) 2020; 12
R Roskoski Jr. (864_CR26) 2016; 103
Y Kobayashi (864_CR67) 2018; 13
Y Liang (864_CR119) 2006; 13
Y Liu (864_CR47) 2021; 12
LWC Chow (864_CR86) 2020; 147
F Rossari (864_CR137) 2018; 11
YF Hsu (864_CR34) 2010; 9
SJ Parsons (864_CR146) 2004; 23
GN Hortobagyi (864_CR174) 2018; 20
K Young (864_CR230) 2015; 8
PH Lizotte (864_CR35) 2018; 6
Y Luo (864_CR190) 2022; 2022
E Cocco (864_CR106) 2018; 15
E Joly (864_CR31) 2003; 4
KN Cho (864_CR161) 2002; 25
M Bekes (864_CR180) 2022; 21
HY Zou (864_CR97) 2007; 67
SH Kim (864_CR234) 2014; 99
AJ Armaghani (864_CR243) 2020; 12
MA Lemmon (864_CR25) 2010; 141
S Assoun (864_CR53) 2019; 45
DMK Keefe (864_CR13) 2019; 2019
MM Awad (864_CR247) 2021; 384
M Talpaz (864_CR237) 2021; 35
CH Heldin (864_CR114) 2013; 11
D Hanahan (864_CR22) 2011; 144
J Liang (864_CR127) 2013; 9
P Wee (864_CR60) 2017; 9
TP Braun (864_CR232) 2020; 37
V Gopalakrishnan (864_CR194) 2018; 359
AJ Cooper (864_CR203) 2022; 19
M Conchon (864_CR233) 2011; 33
R Regeenes (864_CR125) 2018; 293
AT Shaw (864_CR98) 2019; 30
SJ Welsh (864_CR241) 2015; 7
S Qin (864_CR220) 2019; 12
CL Cowey (864_CR223) 2013; 7
T Reungwetwattana (864_CR201) 2021; 6
A Quintas-Cardama (864_CR155) 2013; 19
SV Sharma (864_CR68) 2007; 7
G Fabbrocini (864_CR51) 2015; 1
JY Li (864_CR29) 2021; 20
SC Joosten (864_CR219) 2015; 1855
T Amelia (864_CR62) 2022; 27
M Rose (864_CR178) 2020; 8
864_CR255
H Sung (864_CR1) 2021; 71
JR Johnson (864_CR64) 2005; 11
CJ Lord (864_CR177) 2016; 16
R Yaeger (864_CR157) 2019; 9
T Naito (864_CR101) 2021; 51
M Puttini (864_CR140) 2006; 66
JU Kazi (864_CR108) 2019; 99
CJ Lord (864_CR175) 2017; 355
M Royce (864_CR246) 2022; 40
G Guo (864_CR59) 2015; 75
AE Kersh (864_CR30) 2018; 58
K Jiang (864_CR226) 2021; 10
VL Goodman (864_CR218) 2007; 13
P Charlton (864_CR9) 2016; 44
AF Chauhan (864_CR171) 2021; 13
N Keshava (864_CR189) 2019; 5
RO Dillman (864_CR18) 1999; 14
S Lim (864_CR159) 2013; 140
R Colomer (864_CR17) 2020; 25
CM Della Corte (864_CR92) 2018; 17
MM Seavey (864_CR153) 2012; 83
SP Desikan (864_CR216) 2022; 12
D Rusnak (864_CR82) 2011; 10
References_xml – volume: 8
  start-page: 841
  year: 2017
  end-page: 854
  ident: CR162
  article-title: New tricks for human farnesyltransferase inhibitor: cancer and beyond
  publication-title: Medchemcomm
  doi: 10.1039/C7MD00030H
– volume: 834
  start-page: 188
  year: 2018
  end-page: 196
  ident: CR14
  article-title: Molecular targeted therapy: treating cancer with specificity
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2018.07.034
– volume: 8
  start-page: 935
  year: 2002
  end-page: 942
  ident: CR19
  article-title: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
  publication-title: Clin. Cancer Res.
– volume: 3
  start-page: CMT.S3783
  year: 2011
  ident: CR83
  article-title: Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside
  publication-title: Clin. Med. Insights: Ther.
– volume: 19
  start-page: 327
  year: 2013
  end-page: 335
  ident: CR154
  article-title: The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2087
– volume: 119
  start-page: 1810
  year: 2012
  end-page: 1820
  ident: CR130
  article-title: Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling
  publication-title: Blood
  doi: 10.1182/blood-2011-09-379214
– volume: 16
  start-page: 110
  year: 2016
  end-page: 120
  ident: CR177
  article-title: BRCAness revisited
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2015.21
– volume: 23
  start-page: 7906
  year: 2004
  end-page: 7909
  ident: CR146
  article-title: Src family kinases, key regulators of signal transduction
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208160
– volume: 20
  year: 2020
  ident: CR256
  article-title: Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01614-z
– volume: 23
  start-page: 1698
  year: 2009
  end-page: 1707
  ident: CR138
  article-title: Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2009.111
– volume: 359
  start-page: 97
  year: 2018
  end-page: 103
  ident: CR194
  article-title: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
  publication-title: Science
  doi: 10.1126/science.aan4236
– volume: 14
  start-page: 851
  year: 2021
  end-page: 865
  ident: CR215
  article-title: Safety of FLT3 inhibitors in patients with acute myeloid leukemia
  publication-title: Expert Rev. Hematol.
  doi: 10.1080/17474086.2021.1969911
– volume: 40
  start-page: 883
  year: 2014
  end-page: 891
  ident: CR52
  article-title: Toxicity of targeted therapy: implications for response and impact of genetic polymorphisms
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2014.05.003
– volume: 9
  start-page: 637675
  year: 2021
  ident: CR46
  article-title: The role of tumor-stroma interactions in drug resistance within tumor microenvironment
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.637675
– volume: 75
  start-page: 731
  year: 2015
  end-page: 748
  ident: CR206
  article-title: Panitumumab in metastatic colorectal cancer: the importance of tumour RAS status
  publication-title: Drugs
  doi: 10.1007/s40265-015-0386-x
– volume: 13
  start-page: 113
  year: 2020
  ident: CR167
  article-title: The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-00949-4
– volume: 16
  start-page: 207
  year: 2021
  end-page: 217
  ident: CR253
  article-title: IDH inhibitors in AML-promise and pitfalls
  publication-title: Curr. Hematol. Malig. Rep.
  doi: 10.1007/s11899-021-00619-3
– volume: 1
  start-page: 749283
  year: 2021
  ident: CR111
  article-title: Angiogenesis inhibitors in personalized combination regimens for the treatment of advanced refractory cancers
  publication-title: Front. Mol. Med.
  doi: 10.3389/fmmed.2021.749283
– volume: 4
  start-page: 315
  year: 2020
  end-page: 330
  ident: CR40
  article-title: Nongenetic mechanisms of drug resistance in melanoma
  publication-title: Annu. Rev. Cancer Biol.
  doi: 10.1146/annurev-cancerbio-030419-033533
– volume: 10
  start-page: 342
  year: 2018
  ident: CR90
  article-title: Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer
  publication-title: Cancers
  doi: 10.3390/cancers10100342
– volume: 73
  start-page: 1503
  year: 2013
  end-page: 1515
  ident: CR198
  article-title: Afatinib: first global approval
  publication-title: Drugs
  doi: 10.1007/s40265-013-0111-6
– volume: 82
  start-page: 5350
  year: 2022
  ident: CR78
  article-title: Abstract 5350: OBX02-011, a reversible fourth-generation EGFR-TKI, overcomes C797S-mediated resistance in non-small cell lung cancer
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2022-5350
– volume: 7
  start-page: 493
  year: 2010
  end-page: 507
  ident: CR45
  article-title: Understanding resistance to EGFR inhibitors-impact on future treatment strategies
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2010.97
– volume: 80
  start-page: 2969
  year: 2020
  end-page: 2974
  ident: CR156
  article-title: The frequency of Ras mutations in cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-3682
– volume: 65
  start-page: 3123
  year: 2022
  end-page: 3133
  ident: CR185
  article-title: Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.1c01688
– volume: 28
  start-page: 3411
  year: 2022
  end-page: 3416
  ident: CR249
  article-title: FDA approval summary: decitabine and cedazuridine tablets for myelodysplastic syndromes
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-4498
– volume: 5
  start-page: 875
  year: 2004
  end-page: 885
  ident: CR166
  article-title: The RAF proteins take centre stage
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/nrm1498
– volume: 17
  year: 2018
  ident: CR92
  article-title: Role and targeting of anaplastic lymphoma kinase in cancer
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0776-2
– volume: 168
  start-page: 960
  year: 2017
  end-page: 976
  ident: CR169
  article-title: mTOR signaling in growth, metabolism, and disease
  publication-title: Cell
  doi: 10.1016/j.cell.2017.02.004
– volume: 381
  start-page: 2315
  year: 2019
  end-page: 2326
  ident: CR144
  article-title: Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1902328
– volume: 14
  start-page: 667
  year: 2009
  end-page: 678
  ident: CR147
  article-title: The role of Src in solid tumors
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0009
– volume: 8
  start-page: 98
  year: 2015
  ident: CR173
  article-title: Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-015-0194-5
– volume: 81
  start-page: 1573
  year: 2021
  end-page: 1579
  ident: CR164
  article-title: Sotorasib: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-021-01574-2
– volume: 51
  start-page: 37
  year: 2021
  end-page: 44
  ident: CR101
  article-title: Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases
  publication-title: Jpn. J. Clin. Oncol.
  doi: 10.1093/jjco/hyaa192
– volume: 18
  year: 2019
  ident: CR158
  article-title: Targeting PI3K in cancer: mechanisms and advances in clinical trials
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0954-x
– volume: 6
  start-page: 89
  year: 2015
  end-page: 94
  ident: CR28
  article-title: Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/ml500394m
– volume: 76
  start-page: 263
  year: 2016
  end-page: 273
  ident: CR202
  article-title: Osimertinib: first global approval
  publication-title: Drugs
  doi: 10.1007/s40265-015-0533-4
– volume: 1
  start-page: 1476
  year: 2012
  end-page: 1483
  ident: CR36
  article-title: BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
  publication-title: Oncoimmunology
  doi: 10.4161/onci.21940
– volume: 26
  start-page: 202
  year: 2020
  end-page: 209
  ident: CR49
  article-title: Adverse events of targeted therapies reported by patients with cancer treated in primary care
  publication-title: Eur. J. Gen. Pract.
  doi: 10.1080/13814788.2020.1846713
– volume: 14
  start-page: 6618
  year: 2008
  end-page: 6624
  ident: CR94
  article-title: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1018
– volume: 15
  start-page: 694
  year: 2018
  end-page: 708
  ident: CR213
  article-title: Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-018-0081-4
– volume: 9
  start-page: 800
  year: 2019
  ident: CR58
  article-title: Rethink of EGFR in cancer with its kinase independent function on board
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.00800
– volume: 14
  start-page: 2641
  year: 2022
  ident: CR91
  article-title: Timeline of FDA-approved targeted therapy for cholangiocarcinoma
  publication-title: Cancers
  doi: 10.3390/cancers14112641
– volume: 37
  start-page: 530
  year: 2020
  end-page: 542
  ident: CR232
  article-title: Response and resistance to BCR-ABL1-targeted therapies
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.03.006
– volume: 11
  start-page: 672500
  year: 2021
  ident: CR222
  article-title: Early and next-generation KIT/PDGFRA kinase inhibitors and the future of treatment for advanced gastrointestinal stromal tumor
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.672500
– volume: 9
  year: 2010
  ident: CR34
  article-title: Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
  publication-title: Mol. Cancer
  doi: 10.1186/1476-4598-9-139
– volume: 30
  start-page: 19
  year: 2022
  end-page: 27
  ident: CR74
  article-title: Chronicles of EGFR tyrosine kinase inhibitors: targeting EGFR C797S containing triple mutations
  publication-title: Biomol. Ther.
  doi: 10.4062/biomolther.2021.047
– volume: 8
  start-page: 5
  year: 2022
  ident: CR186
  article-title: KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
  publication-title: Cell Disco.
  doi: 10.1038/s41421-021-00368-w
– volume: 100
  start-page: 1672
  year: 2008
  end-page: 1694
  ident: CR3
  article-title: Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djn389
– volume: 39
  start-page: 3341
  year: 2019
  end-page: 3345
  ident: CR10
  article-title: From ‘targeted therapy’ to targeted therapy
  publication-title: Anticancer Res.
  doi: 10.21873/anticanres.13476
– volume: 385
  start-page: 51
  year: 2017
  end-page: 54
  ident: CR76
  article-title: EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2016.11.008
– volume: 4
  start-page: 815
  year: 2003
  ident: CR31
  article-title: What is trogocytosis and what is its purpose?
  publication-title: Nat. Immunol.
  doi: 10.1038/ni0903-815
– volume: 13
  start-page: 727
  year: 2018
  end-page: 731
  ident: CR67
  article-title: EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2018.01.009
– volume: 141
  start-page: 1117
  year: 2010
  end-page: 1134
  ident: CR25
  article-title: Cell signaling by receptor tyrosine kinases
  publication-title: Cell
  doi: 10.1016/j.cell.2010.06.011
– volume: 35
  start-page: 312
  year: 2021
  end-page: 332
  ident: CR151
  article-title: Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01072-6
– volume: 33
  start-page: 122
  year: 2012
  end-page: 128
  ident: CR148
  article-title: Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2011.11.002
– volume: 81
  start-page: 1107
  year: 2021
  end-page: 1113
  ident: CR72
  article-title: Lazertinib: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-021-01533-x
– volume: 9
  start-page: 52
  year: 2017
  ident: CR60
  article-title: Epidermal growth factor receptor cell proliferation signaling pathways
  publication-title: Cancers
  doi: 10.3390/cancers9050052
– volume: 6
  start-page: 1511
  year: 2018
  end-page: 1523
  ident: CR35
  article-title: A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0193
– volume: 6
  start-page: 5465
  year: 2015
  end-page: 5474
  ident: CR61
  article-title: Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2925
– volume: 11
  start-page: 1617
  year: 2021
  end-page: 1619
  ident: CR81
  article-title: Mobocertinib: a potential treatment for NSCLC with EGFR Exon 20 insertions
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-21-0379
– volume: 7
  start-page: 1074
  year: 2021
  end-page: 1088
  ident: CR227
  article-title: Precision therapy for RET-altered cancers with RET inhibitors
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2021.07.003
– volume: 99
  start-page: 1191
  year: 2014
  end-page: 1196
  ident: CR234
  article-title: Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.096776
– volume: 7
  start-page: 723
  year: 2016
  end-page: 735
  ident: CR204
  article-title: Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer
  publication-title: J. Adv. Pract. Oncol.
– volume: 15
  start-page: 79
  year: 2022
  ident: CR214
  article-title: Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-022-01299-z
– volume: 125
  start-page: 155
  year: 2021
  end-page: 163
  ident: CR4
  article-title: Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01319-8
– volume: 8
  start-page: 3980
  year: 2017
  end-page: 4000
  ident: CR208
  article-title: Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14012
– volume: 19
  start-page: 499
  year: 2022
  end-page: 514
  ident: CR203
  article-title: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-022-00639-9
– volume: 26
  start-page: 3654
  year: 2007
  end-page: 3660
  ident: CR87
  article-title: Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210381
– volume: 9
  start-page: 331
  year: 2009
  end-page: 356
  ident: CR93
  article-title: Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1586/14737140.9.3.331
– volume: 17
  year: 2018
  ident: CR21
  article-title: Kinase-targeted cancer therapies: progress, challenges and future directions
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0804-2
– volume: 8
  start-page: 564601
  year: 2020
  ident: CR178
  article-title: PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.564601
– volume: 8
  start-page: 880
  year: 2008
  end-page: 887
  ident: CR116
  article-title: VEGF-A splicing: the key to anti-angiogenic therapeutics?
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2505
– volume: 13
  start-page: 7237
  year: 2007
  end-page: 7242
  ident: CR251
  article-title: Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-2114
– volume: 25
  start-page: 2949
  year: 2019
  end-page: 2955
  ident: CR210
  article-title: FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-3003
– volume: 42
  start-page: 181
  year: 2019
  end-page: 198
  ident: CR73
  article-title: Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology
  publication-title: Drug Saf.
  doi: 10.1007/s40264-018-0772-x
– volume: 8
  start-page: 235
  year: 2009
  end-page: 253
  ident: CR123
  article-title: The FGF family: biology, pathophysiology and therapy
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd2792
– volume: 13
  start-page: e178
  year: 2012
  end-page: e185
  ident: CR42
  article-title: Genetic heterogeneity and cancer drug resistance
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70335-7
– volume: 140
  start-page: 3079
  year: 2013
  end-page: 3093
  ident: CR159
  article-title: Cdks, cyclins and CKIs: roles beyond cell cycle regulation
  publication-title: Development
  doi: 10.1242/dev.091744
– volume: 3
  start-page: 75ra26
  year: 2011
  ident: CR197
  article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3002003
– volume: 8
  start-page: 109
  year: 2017
  end-page: 125
  ident: CR71
  article-title: Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
  publication-title: Lung Cancer
– volume: 53
  start-page: 199
  year: 2014
  end-page: 204
  ident: CR184
  article-title: Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201307387
– volume: 42
  start-page: 1
  year: 2022
  end-page: 13
  ident: CR183
  article-title: More to the RAS story: KRAS(G12C) inhibition, resistance mechanisms, and moving beyond KRAS(G12C)
  publication-title: Am. Soc. Clin. Oncol. Educ. Book
– volume: 8
  start-page: 111
  year: 2016
  end-page: 120
  ident: CR16
  article-title: Paul Ehrlich (1854–1915) and his contributions to the foundation and birth of translational medicine
  publication-title: J. Innate Immun.
  doi: 10.1159/000443526
– volume: 24
  start-page: 61
  year: 2003
  end-page: 69
  ident: CR132
  article-title: Overexpression of the receptor tyrosine kinase Tie-1 intracellular domain in breast cancer
  publication-title: Tumor Biol.
  doi: 10.1159/000071078
– volume: 66
  start-page: 11314
  year: 2006
  end-page: 11322
  ident: CR140
  article-title: In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-1199
– volume: 3
  start-page: re6
  year: 2010
  ident: CR136
  article-title: ABL tyrosine kinases: evolution of function, regulation, and specificity
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.3139re6
– volume: 9
  start-page: 1980
  year: 2017
  end-page: 1987
  ident: CR199
  article-title: The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd.2017.06.08
– volume: 22
  start-page: 744
  year: 2009
  end-page: 752
  ident: CR131
  article-title: CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2009.43
– volume: 20
  start-page: 651
  year: 2020
  end-page: 658
  ident: CR12
  article-title: A guide to cancer immunotherapy: from T cell basic science to clinical practice
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-0306-5
– volume: 17
  year: 2018
  ident: CR152
  article-title: Role of Bruton’s tyrosine kinase in B cells and malignancies
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0779-z
– volume: 67
  start-page: 4408
  year: 2007
  end-page: 4417
  ident: CR97
  article-title: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-4443
– volume: 7
  start-page: 519
  year: 2013
  end-page: 527
  ident: CR223
  article-title: Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
  publication-title: Drug Des. Devel. Ther.
  doi: 10.2147/DDDT.S31442
– volume: 14
  start-page: 23
  year: 2021
  ident: CR225
  article-title: FGFR-TKI resistance in cancer: current status and perspectives
  publication-title: J. Hematol., Oncol.
  doi: 10.1186/s13045-021-01040-2
– volume: 13
  start-page: 1538
  year: 2021
  ident: CR244
  article-title: Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity
  publication-title: Cancers
  doi: 10.3390/cancers13071538
– volume: 19
  start-page: 1933
  year: 2013
  end-page: 1940
  ident: CR155
  article-title: Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-0284
– volume: 99
  start-page: 1433
  year: 2019
  end-page: 1466
  ident: CR108
  article-title: FMS-like tyrosine kinase 3/FLT3: from basic science to clinical implications
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00029.2018
– volume: 7
  year: 2021
  ident: CR211
  article-title: HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-021-00265-1
– volume: 1
  start-page: 31
  year: 2015
  end-page: 37
  ident: CR51
  article-title: Acneiform rash induced by EGFR inhibitors: review of the literature and new insights
  publication-title: Ski. Appendage Disord.
  doi: 10.1159/000371821
– volume: 8
  start-page: 237
  year: 2017
  end-page: 243
  ident: CR142
  article-title: Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
  publication-title: Ther. Adv. Hematol.
  doi: 10.1177/2040620717719851
– volume: 21
  start-page: 3584
  year: 2015
  end-page: 3585
  ident: CR187
  article-title: Next-generation sequencing: targeting targeted therapies
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-0407
– volume: 9
  start-page: 34
  year: 2020
  ident: CR20
  article-title: Monoclonal antibodies in cancer therapy
  publication-title: Antibodies
  doi: 10.3390/antib9030034
– volume: 11
  start-page: 580251
  year: 2020
  ident: CR245
  article-title: Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.580251
– volume: 30
  start-page: 1121
  year: 2019
  end-page: 1126
  ident: CR98
  article-title: Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz131
– volume: 19
  start-page: 533
  year: 2020
  end-page: 552
  ident: CR181
  article-title: RAS-targeted therapies: is the undruggable drugged?
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-0068-6
– volume: 8
  start-page: 1
  year: 2014
  end-page: 20
  ident: CR254
  article-title: Clinical use of proteasome inhibitors in the treatment of multiple myeloma
  publication-title: Pharmaceuticals
  doi: 10.3390/ph8010001
– volume: 20
  year: 2021
  ident: CR29
  article-title: Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01317-7
– ident: CR149
– volume: 100
  start-page: 107
  year: 2016
  end-page: 116
  ident: CR196
  article-title: Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2016.01.024
– volume: 11
  year: 2013
  ident: CR114
  article-title: Targeting the PDGF signaling pathway in tumor treatment
  publication-title: Cell Commun. Signal.
  doi: 10.1186/1478-811X-11-97
– volume: 40
  start-page: 1155
  year: 2022
  end-page: 1162
  ident: CR246
  article-title: FDA approval summary: abemaciclib with endocrine therapy for high-risk early breast cancer
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.02742
– volume: 7
  start-page: 169
  year: 2007
  end-page: 181
  ident: CR68
  article-title: Epidermal growth factor receptor mutations in lung cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2088
– volume: 12
  start-page: 115
  year: 2021
  end-page: 122
  ident: CR163
  article-title: Spotlight on Sotorasib (AMG 510) for KRAS (G12C) positive non-small cell lung cancer
  publication-title: Lung Cancer
– volume: 11
  year: 2020
  ident: CR170
  article-title: PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-02998-6
– volume: 5
  start-page: 850
  year: 2015
  end-page: 859
  ident: CR105
  article-title: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-15-0285
– volume: 17
  year: 2018
  ident: CR24
  article-title: Mechanisms of receptor tyrosine kinase activation in cancer
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0782-4
– volume: 15
  start-page: 7471
  year: 2009
  end-page: 7478
  ident: CR38
  article-title: Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-1070
– volume: 12
  start-page: 2801
  year: 2020
  ident: CR239
  article-title: Mechanisms of acquired BRAF inhibitor resistance in melanoma: a systematic review
  publication-title: Cancers
  doi: 10.3390/cancers12102801
– volume: 6
  start-page: 201
  year: 2021
  ident: CR8
  article-title: Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00572-w
– volume: 128
  start-page: 331
  year: 2016
  end-page: 336
  ident: CR172
  article-title: Idelalisib in the management of lymphoma
  publication-title: Blood
  doi: 10.1182/blood-2016-02-702761
– volume: 2
  start-page: 257
  year: 2001
  end-page: 267
  ident: CR129
  article-title: Tie receptors: new modulators of angiogenic and lymphangiogenic responses
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/35067005
– volume: 4
  start-page: 1046
  year: 2014
  end-page: 1061
  ident: CR70
  article-title: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-14-0337
– volume: 39
  start-page: 3403
  year: 2021
  end-page: 3406
  ident: CR80
  article-title: Amivantamab: treating EGFR Exon 20-mutant cancers with bispecific antibody-mediated receptor degradation
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.01494
– volume: 27
  start-page: 4974
  year: 2021
  end-page: 4982
  ident: CR107
  article-title: Tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-0465
– volume: 355
  start-page: 1152
  year: 2017
  end-page: 1158
  ident: CR175
  article-title: PARP inhibitors: Synthetic lethality in the clinic
  publication-title: Science
  doi: 10.1126/science.aam7344
– volume: 94
  start-page: 1765
  year: 2006
  end-page: 1769
  ident: CR139
  article-title: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6603170
– volume: 12
  start-page: 635
  year: 2019
  end-page: 645
  ident: CR145
  article-title: Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
  publication-title: Onco. Targets Ther.
  doi: 10.2147/OTT.S189391
– volume: 125
  start-page: 43
  year: 2017
  end-page: 53
  ident: CR5
  article-title: A review of systemic anticancer therapy in disease palliation
  publication-title: Br. Med. Bull.
  doi: 10.1093/bmb/ldx045
– volume: 17
  start-page: 77
  year: 2010
  end-page: 88
  ident: CR104
  article-title: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.11.022
– volume: 12
  start-page: 27
  year: 2019
  ident: CR220
  article-title: Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-019-0718-5
– volume: 6
  start-page: 161
  year: 2021
  end-page: 171
  ident: CR201
  article-title: Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
  publication-title: Expert Rev. Precis. Med. Drug Dev.
  doi: 10.1080/23808993.2021.1909420
– volume: 9
  start-page: 3459
  year: 2015
  end-page: 3470
  ident: CR221
  article-title: Selective use of vandetanib in the treatment of thyroid cancer
  publication-title: Drug Des. Devel. Ther.
– volume: 13
  start-page: 905
  year: 2006
  end-page: 919
  ident: CR119
  article-title: Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones
  publication-title: Endocr. Relat. Cancer
  doi: 10.1677/erc.1.01221
– volume: 599
  start-page: 679
  year: 2021
  end-page: 683
  ident: CR238
  article-title: Diverse alterations associated with resistance to KRAS(G12C) inhibition
  publication-title: Nature
  doi: 10.1038/s41586-021-04065-2
– volume: 37
  start-page: 183
  year: 2020
  end-page: 199
  ident: CR212
  article-title: Hyperactivation of TORC1 drives resistance to the Pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.12.013
– volume: 8
  start-page: 179
  year: 2020
  end-page: 191
  ident: CR88
  article-title: Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
  publication-title: Gastroenterol. Rep.
  doi: 10.1093/gastro/goaa026
– volume: 586
  start-page: 133
  year: 2020
  end-page: 138
  ident: CR193
  article-title: The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic
  publication-title: Nature
  doi: 10.1038/s41586-020-2541-0
– volume: 10
  start-page: 4874
  year: 2021
  end-page: 4884
  ident: CR226
  article-title: GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo
  publication-title: Cancer Med
  doi: 10.1002/cam4.4041
– volume: 37
  start-page: 471
  year: 2020
  end-page: 484
  ident: CR41
  article-title: Intratumor heterogeneity: the rosetta stone of therapy resistance
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.03.007
– volume: 5
  year: 2019
  ident: CR189
  article-title: Defining subpopulations of differential drug response to reveal novel target populations
  publication-title: NPJ Syst. Biol. Appl.
  doi: 10.1038/s41540-019-0113-4
– volume: 71
  start-page: 209
  year: 2021
  end-page: 249
  ident: CR1
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 144
  start-page: 646
  year: 2011
  end-page: 674
  ident: CR22
  article-title: Hallmarks of cancer: the next generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 33
  start-page: 131
  year: 2011
  end-page: 139
  ident: CR233
  article-title: Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
  publication-title: Rev. Bras. Hematol. Hemoter.
  doi: 10.5581/1516-8484.20110034
– volume: 8
  start-page: 373
  year: 2015
  end-page: 383
  ident: CR230
  article-title: Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
  publication-title: Ther. Adv. Gastroenterol.
  doi: 10.1177/1756283X15592586
– volume: 18
  start-page: 1054
  year: 2004
  end-page: 1058
  ident: CR118
  article-title: Crosstalk between angiogenesis and lymphangiogenesis in tumor progression
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403355
– volume: 103
  start-page: 26
  year: 2016
  end-page: 48
  ident: CR26
  article-title: Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2015.10.021
– volume: 15
  start-page: 731
  year: 2018
  end-page: 747
  ident: CR106
  article-title: NTRK fusion-positive cancers and TRK inhibitor therapy
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-018-0113-0
– volume: 438
  start-page: 820
  year: 2005
  end-page: 827
  ident: CR122
  article-title: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
  publication-title: Nature
  doi: 10.1038/nature04186
– volume: 79
  start-page: 34
  year: 2014
  end-page: 74
  ident: CR54
  article-title: The ErbB/HER family of protein-tyrosine kinases and cancer
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2013.11.002
– volume: 44
  start-page: 34
  year: 2016
  end-page: 38
  ident: CR9
  article-title: Targeted therapy in cancer
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.012
– volume: 5
  start-page: 228
  year: 2020
  ident: CR48
  article-title: Emerging role of tumor cell plasticity in modifying therapeutic response
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00313-5
– volume: 24
  start-page: 1216
  year: 2010
  end-page: 1220
  ident: CR110
  article-title: Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways
  publication-title: Leukemia
  doi: 10.1038/leu.2010.73
– volume: 27
  start-page: 819
  year: 2022
  ident: CR62
  article-title: Structural insight and development of EGFR tyrosine kinase inhibitors
  publication-title: Molecules
  doi: 10.3390/molecules27030819
– volume: 10
  start-page: 4233s
  year: 2004
  end-page: 4237s
  ident: CR63
  article-title: The role of gefitinib in lung cancer treatment
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-040005
– volume: 86
  start-page: 102017
  year: 2020
  ident: CR229
  article-title: Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2020.102017
– volume: 210
  start-page: 107522
  year: 2020
  ident: CR43
  article-title: Acquired resistance to targeted therapies in NSCLC: updates and evolving insights
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2020.107522
– volume: 12
  start-page: 1443
  year: 2007
  end-page: 1455
  ident: CR50
  article-title: Review: side effects of approved molecular targeted therapies in solid cancers
  publication-title: Oncologist
  doi: 10.1634/theoncologist.12-12-1443
– volume: 23
  start-page: 3946
  year: 2018
  end-page: 3959
  ident: CR33
  article-title: Neutrophils kill antibody-opsonized cancer cells by trogoptosis
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2018.05.082
– volume: 11
  start-page: 84
  year: 2018
  ident: CR137
  article-title: Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-018-0624-2
– volume: 121
  start-page: 725
  year: 2019
  end-page: 737
  ident: CR75
  article-title: Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-019-0573-8
– volume: 10
  start-page: 176
  year: 2005
  end-page: 182
  ident: CR248
  article-title: FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension
  publication-title: Oncologist
  doi: 10.1634/theoncologist.10-3-176
– volume: 21
  start-page: 181
  year: 2022
  end-page: 200
  ident: CR180
  article-title: PROTAC targeted protein degraders: the past is prologue
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00371-6
– volume: 13
  start-page: 677
  year: 2021
  end-page: 692
  ident: CR171
  article-title: Copanlisib in the treatment of relapsed follicular lymphoma: utility and experience from the clinic
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S201024
– ident: CR255
– volume: 98
  start-page: e16785
  year: 2019
  ident: CR231
  article-title: Pattern of adverse events induced by aflibercept and ranibizumab: a nationwide spontaneous adverse event reporting database, 2007–2016
  publication-title: Medicine
  doi: 10.1097/MD.0000000000016785
– volume: 13
  start-page: 1367
  year: 2007
  end-page: 1373
  ident: CR218
  article-title: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-2328
– volume: 44
  start-page: 30
  year: 2016
  end-page: 33
  ident: CR11
  article-title: Hormonal therapy for cancer
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.014
– volume: 15
  start-page: 2207
  year: 2009
  end-page: 2214
  ident: CR103
  article-title: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1306
– volume: 1834
  start-page: 2176
  year: 2013
  end-page: 2186
  ident: CR112
  article-title: Platelet-derived growth factors and their receptors: structural and functional perspectives
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbapap.2012.10.015
– volume: 19
  start-page: 976
  year: 2020
  end-page: 987
  ident: CR85
  article-title: Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-19-0873
– volume: 59
  start-page: 13764
  year: 2020
  end-page: 13776
  ident: CR27
  article-title: New promise and opportunities for allosteric kinase inhibitors
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201914525
– volume: 134
  start-page: 741
  year: 2019
  end-page: 745
  ident: CR109
  article-title: Availability of FLT3 inhibitors: how do we use them?
  publication-title: Blood
  doi: 10.1182/blood.2019876821
– volume: 25
  start-page: 759
  year: 2002
  end-page: 769
  ident: CR161
  article-title: Chemistry and biology of Ras farnesyltransferase
  publication-title: Arch. Pharm. Res.
  doi: 10.1007/BF02976989
– volume: 62
  start-page: 1556
  year: 2016
  end-page: 1564
  ident: CR15
  article-title: The use of targeted therapies for precision medicine in oncology
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2015.247882
– volume: 78
  start-page: 549
  year: 2018
  end-page: 566
  ident: CR240
  article-title: BRAF and MEK inhibitors: use and resistance in BRAF-mutated cancers
  publication-title: Drugs
  doi: 10.1007/s40265-018-0884-8
– volume: 2022
  start-page: 9816939
  year: 2022
  ident: CR190
  article-title: Next Decade’s AI-based drug development features tight integration of data and computation
  publication-title: Health Data Sci.
  doi: 10.34133/2022/9816939
– volume: 22
  start-page: 5527
  year: 2016
  end-page: 5538
  ident: CR102
  article-title: The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-0569
– volume: 61
  start-page: 8120
  year: 2018
  end-page: 8135
  ident: CR143
  article-title: Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01040
– volume: 75
  start-page: 3436
  year: 2015
  end-page: 3441
  ident: CR59
  article-title: Ligand-independent EGFR signaling
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0989
– volume: 124
  start-page: 1757
  year: 2021
  end-page: 1758
  ident: CR228
  article-title: An early look at selective RET inhibitor resistance: new challenges and opportunities
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01344-7
– volume: 35
  start-page: 1317
  year: 2021
  end-page: 1329
  ident: CR236
  article-title: BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01123-6
– volume: 15
  start-page: 563
  year: 2019
  end-page: 570
  ident: CR100
  article-title: Management of brain metastases in non–small-cell lung cancer
  publication-title: JCO Oncol. Pract.
  doi: 10.1200/JOP.19.00357
– volume: 5
  start-page: 1706
  year: 2010
  end-page: 1713
  ident: CR57
  article-title: Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181f1c8de
– volume: 10
  start-page: 2019
  year: 2011
  ident: CR82
  article-title: The discovery of lapatinib (GW572016)
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0697
– volume: 5
  start-page: 181
  year: 2020
  ident: CR126
  article-title: FGF/FGFR signaling in health and disease
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00222-7
– volume: 9
  start-page: 435
  year: 2013
  end-page: 443
  ident: CR127
  article-title: The C-kit receptor-mediated signal transduction and tumor-related diseases
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.6087
– ident: CR205
– volume: 8
  start-page: 579
  year: 2008
  end-page: 591
  ident: CR115
  article-title: VEGF-targeted therapy: mechanisms of anti-tumour activity
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2403
– volume: 14
  start-page: 5
  year: 1999
  end-page: 10
  ident: CR18
  article-title: Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer
  publication-title: Cancer Biother. Radiopharm.
  doi: 10.1089/cbr.1999.14.5
– volume: 58
  start-page: 7
  year: 2018
  end-page: 24
  ident: CR30
  article-title: Targeted therapies: immunologic effects and potential applications outside of cancer
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.1028
– volume: 12
  start-page: 645864
  year: 2021
  ident: CR47
  article-title: E3 ubiquitin ligase in anticancer drugdsla resistance: recent advances and future potential
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.645864
– volume: 25
  start-page: 3759
  year: 2019
  end-page: 3771
  ident: CR176
  article-title: PARP inhibitors: extending benefit beyond BRCA-mutant cancers
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0968
– volume: 12
  start-page: 251
  year: 2020
  end-page: 258
  ident: CR243
  article-title: Alpelisib in the treatment of breast cancer: a short review on the emerging clinical data
  publication-title: Breast Cancer
– volume: 44
  start-page: 20
  year: 2016
  end-page: 24
  ident: CR6
  article-title: Principles of systemic anticancer therapy
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.009
– volume: 17
  start-page: 93
  year: 2017
  end-page: 115
  ident: CR160
  article-title: Cell cycle proteins as promising targets in cancer therapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.138
– ident: CR84
– volume: 9
  start-page: 329
  year: 2019
  end-page: 341
  ident: CR157
  article-title: Targeting alterations in the RAF-MEK pathway
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-18-1321
– volume: 92
  start-page: 102137
  year: 2021
  ident: CR242
  article-title: MEK inhibitor resistance mechanisms and recent developments in combination trials
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2020.102137
– volume: 34
  start-page: 3107
  year: 2015
  end-page: 3119
  ident: CR121
  article-title: VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
  publication-title: Oncogene
  doi: 10.1038/onc.2014.257
– volume: 27
  start-page: 4702
  year: 2008
  end-page: 4711
  ident: CR65
  article-title: BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  publication-title: Oncogene
  doi: 10.1038/onc.2008.109
– volume: 12
  start-page: 5268
  year: 2006
  end-page: 5272
  ident: CR55
  article-title: The epidermal growth factor receptor pathway: a model for targeted therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-1554
– volume: 87
  start-page: 4577
  year: 2021
  end-page: 4597
  ident: CR250
  article-title: Recent developments of HDAC inhibitors: emerging indications and novel molecules
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/bcp.14889
– volume: 17
  start-page: 2127
  year: 2021
  end-page: 2140
  ident: CR252
  article-title: EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
  publication-title: Future Oncol.
  doi: 10.2217/fon-2020-1244
– volume: 1
  start-page: 69
  year: 2017
  end-page: 75
  ident: CR2
  article-title: Molecular targeted therapy of cancer: the progress and future prospect
  publication-title: Front. Lab. Med.
  doi: 10.1016/j.flm.2017.06.001
– volume: 17
  year: 2018
  ident: CR96
  article-title: The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0810-4
– volume: 19
  start-page: 3491
  year: 2018
  ident: CR134
  article-title: Receptor tyrosine kinase-targeted cancer therapy
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19113491
– volume: 13
  start-page: 2968
  year: 2021
  ident: CR224
  article-title: FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice
  publication-title: Cancers
  doi: 10.3390/cancers13122968
– volume: 2020
  start-page: 336
  year: 2020
  end-page: 345
  ident: CR235
  article-title: Managing toxicities of Bruton tyrosine kinase inhibitors
  publication-title: Hematol. Am. Soc. Hematol. Educ. Program
  doi: 10.1182/hematology.2020000118
– volume: 20
  year: 2018
  ident: CR174
  article-title: Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-018-1050-7
– volume: 13
  start-page: 1758835921992976
  year: 2021
  ident: CR99
  article-title: Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758835921992976
– volume: 4
  start-page: 1
  year: 2009
  end-page: 4
  ident: CR69
  article-title: EGFR T790M mutation: a double role in lung cancer cell survival?
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181913c9f
– volume: 79
  start-page: 823
  year: 2019
  end-page: 831
  ident: CR66
  article-title: Dacomitinib in the management of advanced non-small-cell lung cancer
  publication-title: Drugs
  doi: 10.1007/s40265-019-01115-y
– volume: 7
  start-page: 122
  year: 2015
  end-page: 136
  ident: CR241
  article-title: Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758834014566428
– volume: 83
  start-page: 1136
  year: 2012
  end-page: 1145
  ident: CR153
  article-title: The many faces of Janus kinase
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2011.12.024
– volume: 384
  start-page: 2382
  year: 2021
  end-page: 2393
  ident: CR247
  article-title: Acquired resistance to KRAS(G12C) inhibition in cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2105281
– volume: 10
  start-page: 1255
  year: 2021
  ident: CR32
  article-title: The role of trogocytosis in the modulation of immune cell functions
  publication-title: Cells
  doi: 10.3390/cells10051255
– volume: 25
  start-page: 100487
  year: 2020
  ident: CR17
  article-title: When should we order a next generation sequencing test in a patient with cancer?
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2020.100487
– volume: 150
  start-page: 113064
  year: 2022
  ident: CR44
  article-title: The multi-molecular mechanisms of tumor-targeted drug resistance in precision medicine
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2022.113064
– volume: 151
  start-page: 104567
  year: 2020
  ident: CR133
  article-title: The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104567
– volume: 9
  start-page: 332
  year: 2005
  end-page: 338
  ident: CR207
  article-title: Cetuximab: adverse event profile and recommendations for toxicity management
  publication-title: Clin. J. Oncol. Nurs.
  doi: 10.1188/05.CJON.332-338
– volume: 1855
  start-page: 1
  year: 2015
  end-page: 16
  ident: CR219
  article-title: Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives
  publication-title: Biochim. Biophys. Acta
– volume: 17
  start-page: 296
  year: 2021
  end-page: 306
  ident: CR128
  article-title: The importance of the RET gene in thyroid cancer and therapeutic implications
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/s41574-021-00470-9
– volume: 387
  start-page: 120
  year: 2022
  end-page: 131
  ident: CR165
  article-title: Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2204619
– volume: 293
  start-page: 17218
  year: 2018
  end-page: 17228
  ident: CR125
  article-title: Fibroblast growth factor receptor 5 (FGFR5) is a co-receptor for FGFR1 that is up-regulated in beta-cells by cytokine-induced inflammation
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.003036
– volume: 41
  start-page: 1701
  year: 2021
  end-page: 1750
  ident: CR179
  article-title: Drug design targeting active posttranslational modification protein isoforms
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21774
– volume: 11
  start-page: 6414
  year: 2005
  end-page: 6421
  ident: CR64
  article-title: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-0790
– volume: 13
  start-page: 559
  year: 2013
  end-page: 571
  ident: CR135
  article-title: Role of ABL family kinases in cancer: from leukaemia to solid tumours
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3563
– volume: 7
  start-page: 212
  year: 2018
  ident: CR195
  article-title: Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy
  publication-title: Cells
  doi: 10.3390/cells7110212
– volume: 16
  start-page: 800
  year: 2011
  end-page: 810
  ident: CR209
  article-title: Trastuzumab
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0035
– volume: 28
  start-page: iv41
  year: 2017
  end-page: iv51
  ident: CR141
  article-title: Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx219
– volume: 44
  start-page: 2806
  year: 2008
  end-page: 2812
  ident: CR56
  article-title: Her2-positive breast cancer: herceptin and beyond
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.09.013
– volume: 40
  start-page: 964
  year: 2021
  end-page: 979
  ident: CR120
  article-title: VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01539-x
– volume: 35
  start-page: 1
  year: 2021
  end-page: 17
  ident: CR237
  article-title: Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0954-2
– volume: 22
  start-page: 1276
  year: 2008
  end-page: 1312
  ident: CR113
  article-title: Role of platelet-derived growth factors in physiology and medicine
  publication-title: Genes Dev.
  doi: 10.1101/gad.1653708
– volume: 12
  year: 2022
  ident: CR216
  article-title: Resistance to targeted therapies: delving into FLT3 and IDH
  publication-title: Blood Cancer J.
  doi: 10.1038/s41408-022-00687-5
– volume: 45
  start-page: 988
  year: 2019
  end-page: 997
  ident: CR53
  article-title: Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases
  publication-title: Intensive Care Med.
  doi: 10.1007/s00134-019-05650-w
– volume: 111
  start-page: 3445
  year: 2020
  end-page: 3457
  ident: CR188
  article-title: Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy
  publication-title: Cancer Sci.
  doi: 10.1111/cas.14609
– volume: 70
  start-page: 1059
  year: 2010
  end-page: 1078
  ident: CR89
  article-title: Panitumumab: a review of its use in metastatic colorectal cancer
  publication-title: Drugs
  doi: 10.2165/11205090-000000000-00000
– volume: 7
  start-page: 172
  year: 2019
  ident: CR37
  article-title: Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0643-8
– volume: 170
  start-page: 712
  year: 2013
  end-page: 729
  ident: CR117
  article-title: Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12344
– volume: 30
  start-page: 125
  year: 2018
  end-page: 133
  ident: CR168
  article-title: Development of encorafenib for BRAF-mutated advanced melanoma
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0000000000000426
– volume: 20
  start-page: 551
  year: 2021
  end-page: 569
  ident: CR23
  article-title: Kinase drug discovery 20 years after imatinib: progress and future directions
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00195-4
– volume: 12
  start-page: 1448
  year: 2020
  ident: CR150
  article-title: Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned so Far
  publication-title: Cancers
  doi: 10.3390/cancers12061448
– volume: 21
  start-page: 2227
  year: 2015
  end-page: 2235
  ident: CR95
  article-title: Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-2791
– volume: 17
  start-page: 318
  year: 2017
  end-page: 332
  ident: CR124
  article-title: Advances and challenges in targeting FGFR signalling in cancer
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.8
– volume: 1877
  start-page: 188666
  year: 2022
  ident: CR217
  article-title: The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors
  publication-title: Biochim. Biophys. Acta Rev. Cancer
  doi: 10.1016/j.bbcan.2021.188666
– volume: 54
  start-page: 315
  year: 2022
  end-page: 329
  ident: CR79
  article-title: Challenges in the use of targeted therapies in non-small cell lung cancer
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2022.078
– volume: 6
  start-page: 86
  year: 2020
  end-page: 97
  ident: CR192
  article-title: The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2019.12.007
– volume: 8
  start-page: 394
  year: 2019
  ident: CR257
  article-title: Recent advances in the clinical targeting of hedgehog/GLI signaling in cancer
  publication-title: Cells
  doi: 10.3390/cells8050394
– volume: 44
  start-page: 25
  year: 2016
  end-page: 29
  ident: CR7
  article-title: Cytotoxic chemotherapy: clinical aspects
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.007
– volume: 147
  start-page: 375
  year: 2020
  end-page: 428
  ident: CR86
  article-title: Advances in EGFR/HER2-directed clinical research on breast cancer
  publication-title: Adv. Cancer Res.
  doi: 10.1016/bs.acr.2020.04.009
– volume: 12
  start-page: 755053
  year: 2022
  ident: CR39
  article-title: Evolution of molecular targeted cancer therapy: mechanisms of drug resistance and novel opportunities identified by CRISPR-Cas9 screening
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.755053
– volume: 31
  start-page: S839
  year: 2020
  ident: CR77
  article-title: 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.08.1610
– volume: 78
  start-page: 1947
  year: 2018
  end-page: 1953
  ident: CR200
  article-title: Dacomitinib: first global approval
  publication-title: Drugs
  doi: 10.1007/s40265-018-1028-x
– volume: 71
  start-page: 1412
  year: 2022
  end-page: 1425
  ident: CR191
  article-title: Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
  publication-title: Gut
  doi: 10.1136/gutjnl-2021-326264
– volume: 503
  start-page: 548
  year: 2013
  end-page: 551
  ident: CR182
  article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
  publication-title: Nature
  doi: 10.1038/nature12796
– volume: 2019
  start-page: lgz008
  year: 2019
  ident: CR13
  article-title: Potential successes and challenges of targeted cancer therapies
  publication-title: J. Natl Cancer Inst. Monogr.
  doi: 10.1093/jncimonographs/lgz008
– volume: 5
  start-page: 1706
  year: 2010
  ident: 864_CR57
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181f1c8de
– volume: 1
  start-page: 31
  year: 2015
  ident: 864_CR51
  publication-title: Ski. Appendage Disord.
  doi: 10.1159/000371821
– volume: 7
  start-page: 172
  year: 2019
  ident: 864_CR37
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-019-0643-8
– volume: 2020
  start-page: 336
  year: 2020
  ident: 864_CR235
  publication-title: Hematol. Am. Soc. Hematol. Educ. Program
  doi: 10.1182/hematology.2020000118
– volume: 3
  start-page: re6
  year: 2010
  ident: 864_CR136
  publication-title: Sci. Signal.
  doi: 10.1126/scisignal.3139re6
– volume: 5
  start-page: 850
  year: 2015
  ident: 864_CR105
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-15-0285
– volume: 9
  start-page: 435
  year: 2013
  ident: 864_CR127
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.6087
– volume: 11
  year: 2020
  ident: 864_CR170
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-020-02998-6
– volume: 134
  start-page: 741
  year: 2019
  ident: 864_CR109
  publication-title: Blood
  doi: 10.1182/blood.2019876821
– volume: 6
  start-page: 161
  year: 2021
  ident: 864_CR201
  publication-title: Expert Rev. Precis. Med. Drug Dev.
  doi: 10.1080/23808993.2021.1909420
– volume: 76
  start-page: 263
  year: 2016
  ident: 864_CR202
  publication-title: Drugs
  doi: 10.1007/s40265-015-0533-4
– volume: 6
  start-page: 5465
  year: 2015
  ident: 864_CR61
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2925
– volume: 12
  start-page: 1448
  year: 2020
  ident: 864_CR150
  publication-title: Cancers
  doi: 10.3390/cancers12061448
– volume: 75
  start-page: 3436
  year: 2015
  ident: 864_CR59
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0989
– volume: 26
  start-page: 3654
  year: 2007
  ident: 864_CR87
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210381
– volume: 6
  start-page: 201
  year: 2021
  ident: 864_CR8
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-021-00572-w
– volume: 385
  start-page: 51
  year: 2017
  ident: 864_CR76
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2016.11.008
– volume: 12
  start-page: 27
  year: 2019
  ident: 864_CR220
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-019-0718-5
– volume: 13
  start-page: 7237
  year: 2007
  ident: 864_CR251
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-2114
– volume: 61
  start-page: 8120
  year: 2018
  ident: 864_CR143
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01040
– volume: 15
  start-page: 694
  year: 2018
  ident: 864_CR213
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-018-0081-4
– volume: 6
  start-page: 86
  year: 2020
  ident: 864_CR192
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2019.12.007
– volume: 5
  start-page: 181
  year: 2020
  ident: 864_CR126
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00222-7
– volume: 210
  start-page: 107522
  year: 2020
  ident: 864_CR43
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2020.107522
– volume: 19
  start-page: 976
  year: 2020
  ident: 864_CR85
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-19-0873
– volume: 25
  start-page: 100487
  year: 2020
  ident: 864_CR17
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2020.100487
– volume: 7
  start-page: 212
  year: 2018
  ident: 864_CR195
  publication-title: Cells
  doi: 10.3390/cells7110212
– volume: 23
  start-page: 3946
  year: 2018
  ident: 864_CR33
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2018.05.082
– volume: 40
  start-page: 883
  year: 2014
  ident: 864_CR52
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2014.05.003
– volume: 293
  start-page: 17218
  year: 2018
  ident: 864_CR125
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA118.003036
– volume: 19
  start-page: 533
  year: 2020
  ident: 864_CR181
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-0068-6
– volume: 24
  start-page: 61
  year: 2003
  ident: 864_CR132
  publication-title: Tumor Biol.
  doi: 10.1159/000071078
– volume: 5
  year: 2019
  ident: 864_CR189
  publication-title: NPJ Syst. Biol. Appl.
  doi: 10.1038/s41540-019-0113-4
– volume: 14
  start-page: 5
  year: 1999
  ident: 864_CR18
  publication-title: Cancer Biother. Radiopharm.
  doi: 10.1089/cbr.1999.14.5
– volume: 7
  start-page: 493
  year: 2010
  ident: 864_CR45
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/nrclinonc.2010.97
– volume: 13
  start-page: 727
  year: 2018
  ident: 864_CR67
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2018.01.009
– volume: 13
  start-page: 2968
  year: 2021
  ident: 864_CR224
  publication-title: Cancers
  doi: 10.3390/cancers13122968
– volume: 8
  start-page: 579
  year: 2008
  ident: 864_CR115
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2403
– volume: 13
  start-page: 1367
  year: 2007
  ident: 864_CR218
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-06-2328
– volume: 4
  start-page: 315
  year: 2020
  ident: 864_CR40
  publication-title: Annu. Rev. Cancer Biol.
  doi: 10.1146/annurev-cancerbio-030419-033533
– volume: 1
  start-page: 69
  year: 2017
  ident: 864_CR2
  publication-title: Front. Lab. Med.
  doi: 10.1016/j.flm.2017.06.001
– volume: 41
  start-page: 1701
  year: 2021
  ident: 864_CR179
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21774
– volume: 119
  start-page: 1810
  year: 2012
  ident: 864_CR130
  publication-title: Blood
  doi: 10.1182/blood-2011-09-379214
– volume: 16
  start-page: 800
  year: 2011
  ident: 864_CR209
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0035
– volume: 100
  start-page: 107
  year: 2016
  ident: 864_CR196
  publication-title: Crit. Rev. Oncol. Hematol.
  doi: 10.1016/j.critrevonc.2016.01.024
– ident: 864_CR255
  doi: 10.1007/978-3-030-73440-4_4
– volume: 151
  start-page: 104567
  year: 2020
  ident: 864_CR133
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104567
– volume: 86
  start-page: 102017
  year: 2020
  ident: 864_CR229
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2020.102017
– volume: 42
  start-page: 181
  year: 2019
  ident: 864_CR73
  publication-title: Drug Saf.
  doi: 10.1007/s40264-018-0772-x
– volume: 66
  start-page: 11314
  year: 2006
  ident: 864_CR140
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-1199
– volume: 10
  start-page: 342
  year: 2018
  ident: 864_CR90
  publication-title: Cancers
  doi: 10.3390/cancers10100342
– volume: 21
  start-page: 181
  year: 2022
  ident: 864_CR180
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00371-6
– volume: 170
  start-page: 712
  year: 2013
  ident: 864_CR117
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/bph.12344
– volume: 83
  start-page: 1136
  year: 2012
  ident: 864_CR153
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2011.12.024
– volume: 3
  start-page: 75ra26
  year: 2011
  ident: 864_CR197
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.3002003
– volume: 4
  start-page: 1046
  year: 2014
  ident: 864_CR70
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-14-0337
– volume: 24
  start-page: 1216
  year: 2010
  ident: 864_CR110
  publication-title: Leukemia
  doi: 10.1038/leu.2010.73
– volume: 34
  start-page: 3107
  year: 2015
  ident: 864_CR121
  publication-title: Oncogene
  doi: 10.1038/onc.2014.257
– volume: 10
  start-page: 176
  year: 2005
  ident: 864_CR248
  publication-title: Oncologist
  doi: 10.1634/theoncologist.10-3-176
– volume: 58
  start-page: 7
  year: 2018
  ident: 864_CR30
  publication-title: J. Clin. Pharmacol.
  doi: 10.1002/jcph.1028
– volume: 9
  start-page: 332
  year: 2005
  ident: 864_CR207
  publication-title: Clin. J. Oncol. Nurs.
  doi: 10.1188/05.CJON.332-338
– volume: 1834
  start-page: 2176
  year: 2013
  ident: 864_CR112
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbapap.2012.10.015
– volume: 18
  year: 2019
  ident: 864_CR158
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-019-0954-x
– volume: 9
  start-page: 52
  year: 2017
  ident: 864_CR60
  publication-title: Cancers
  doi: 10.3390/cancers9050052
– volume: 94
  start-page: 1765
  year: 2006
  ident: 864_CR139
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6603170
– volume: 11
  start-page: 1617
  year: 2021
  ident: 864_CR81
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-21-0379
– volume: 8
  start-page: 179
  year: 2020
  ident: 864_CR88
  publication-title: Gastroenterol. Rep.
  doi: 10.1093/gastro/goaa026
– volume: 503
  start-page: 548
  year: 2013
  ident: 864_CR182
  publication-title: Nature
  doi: 10.1038/nature12796
– volume: 79
  start-page: 823
  year: 2019
  ident: 864_CR66
  publication-title: Drugs
  doi: 10.1007/s40265-019-01115-y
– volume: 9
  start-page: 1980
  year: 2017
  ident: 864_CR199
  publication-title: J. Thorac. Dis.
  doi: 10.21037/jtd.2017.06.08
– volume: 44
  start-page: 20
  year: 2016
  ident: 864_CR6
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.009
– volume: 79
  start-page: 34
  year: 2014
  ident: 864_CR54
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2013.11.002
– volume: 4
  start-page: 1
  year: 2009
  ident: 864_CR69
  publication-title: J. Thorac. Oncol.
  doi: 10.1097/JTO.0b013e3181913c9f
– volume: 35
  start-page: 312
  year: 2021
  ident: 864_CR151
  publication-title: Leukemia
  doi: 10.1038/s41375-020-01072-6
– volume: 20
  start-page: 651
  year: 2020
  ident: 864_CR12
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-0306-5
– volume: 9
  start-page: 34
  year: 2020
  ident: 864_CR20
  publication-title: Antibodies
  doi: 10.3390/antib9030034
– volume: 103
  start-page: 26
  year: 2016
  ident: 864_CR26
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2015.10.021
– volume: 81
  start-page: 1573
  year: 2021
  ident: 864_CR164
  publication-title: Drugs
  doi: 10.1007/s40265-021-01574-2
– volume: 834
  start-page: 188
  year: 2018
  ident: 864_CR14
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2018.07.034
– volume: 20
  year: 2021
  ident: 864_CR29
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01317-7
– volume: 8
  start-page: 98
  year: 2015
  ident: 864_CR173
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-015-0194-5
– volume: 17
  year: 2018
  ident: 864_CR152
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0779-z
– volume: 20
  start-page: 551
  year: 2021
  ident: 864_CR23
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-021-00195-4
– volume: 17
  start-page: 2127
  year: 2021
  ident: 864_CR252
  publication-title: Future Oncol.
  doi: 10.2217/fon-2020-1244
– volume: 39
  start-page: 3403
  year: 2021
  ident: 864_CR80
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.01494
– volume: 100
  start-page: 1672
  year: 2008
  ident: 864_CR3
  publication-title: J. Natl Cancer Inst.
  doi: 10.1093/jnci/djn389
– volume: 27
  start-page: 4974
  year: 2021
  ident: 864_CR107
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-0465
– volume: 384
  start-page: 2382
  year: 2021
  ident: 864_CR247
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2105281
– volume: 1
  start-page: 1476
  year: 2012
  ident: 864_CR36
  publication-title: Oncoimmunology
  doi: 10.4161/onci.21940
– volume: 12
  start-page: 5268
  year: 2006
  ident: 864_CR55
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-1554
– volume: 16
  start-page: 110
  year: 2016
  ident: 864_CR177
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2015.21
– volume: 12
  start-page: 645864
  year: 2021
  ident: 864_CR47
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.645864
– volume: 14
  start-page: 2641
  year: 2022
  ident: 864_CR91
  publication-title: Cancers
  doi: 10.3390/cancers14112641
– volume: 2022
  start-page: 9816939
  year: 2022
  ident: 864_CR190
  publication-title: Health Data Sci.
  doi: 10.34133/2022/9816939
– volume: 12
  year: 2022
  ident: 864_CR216
  publication-title: Blood Cancer J.
  doi: 10.1038/s41408-022-00687-5
– volume: 42
  start-page: 1
  year: 2022
  ident: 864_CR183
  publication-title: Am. Soc. Clin. Oncol. Educ. Book
– volume: 13
  start-page: 113
  year: 2020
  ident: 864_CR167
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-020-00949-4
– volume: 11
  start-page: 672500
  year: 2021
  ident: 864_CR222
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.672500
– volume: 12
  start-page: 635
  year: 2019
  ident: 864_CR145
  publication-title: Onco. Targets Ther.
  doi: 10.2147/OTT.S189391
– volume: 3
  start-page: CMT.S3783
  year: 2011
  ident: 864_CR83
  publication-title: Clin. Med. Insights: Ther.
– volume: 6
  start-page: 89
  year: 2015
  ident: 864_CR28
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/ml500394m
– volume: 150
  start-page: 113064
  year: 2022
  ident: 864_CR44
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2022.113064
– volume: 8
  start-page: 394
  year: 2019
  ident: 864_CR257
  publication-title: Cells
  doi: 10.3390/cells8050394
– volume: 20
  year: 2020
  ident: 864_CR256
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01614-z
– volume: 23
  start-page: 7906
  year: 2004
  ident: 864_CR146
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208160
– volume: 599
  start-page: 679
  year: 2021
  ident: 864_CR238
  publication-title: Nature
  doi: 10.1038/s41586-021-04065-2
– ident: 864_CR205
  doi: 10.4161/cbt.5.4.2666
– volume: 26
  start-page: 202
  year: 2020
  ident: 864_CR49
  publication-title: Eur. J. Gen. Pract.
  doi: 10.1080/13814788.2020.1846713
– volume: 25
  start-page: 759
  year: 2002
  ident: 864_CR161
  publication-title: Arch. Pharm. Res.
  doi: 10.1007/BF02976989
– volume: 8
  start-page: 841
  year: 2017
  ident: 864_CR162
  publication-title: Medchemcomm
  doi: 10.1039/C7MD00030H
– volume: 11
  start-page: 580251
  year: 2020
  ident: 864_CR245
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.580251
– volume: 9
  start-page: 3459
  year: 2015
  ident: 864_CR221
  publication-title: Drug Des. Devel. Ther.
– volume: 8
  start-page: 880
  year: 2008
  ident: 864_CR116
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2505
– volume: 19
  start-page: 3491
  year: 2018
  ident: 864_CR134
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19113491
– volume: 37
  start-page: 471
  year: 2020
  ident: 864_CR41
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.03.007
– volume: 141
  start-page: 1117
  year: 2010
  ident: 864_CR25
  publication-title: Cell
  doi: 10.1016/j.cell.2010.06.011
– volume: 13
  start-page: e178
  year: 2012
  ident: 864_CR42
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(11)70335-7
– volume: 9
  year: 2010
  ident: 864_CR34
  publication-title: Mol. Cancer
  doi: 10.1186/1476-4598-9-139
– volume: 11
  start-page: 84
  year: 2018
  ident: 864_CR137
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-018-0624-2
– volume: 80
  start-page: 2969
  year: 2020
  ident: 864_CR156
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-3682
– volume: 9
  start-page: 637675
  year: 2021
  ident: 864_CR46
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.637675
– volume: 44
  start-page: 30
  year: 2016
  ident: 864_CR11
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.014
– volume: 75
  start-page: 731
  year: 2015
  ident: 864_CR206
  publication-title: Drugs
  doi: 10.1007/s40265-015-0386-x
– volume: 20
  year: 2018
  ident: 864_CR174
  publication-title: Breast Cancer Res
  doi: 10.1186/s13058-018-1050-7
– volume: 35
  start-page: 1
  year: 2021
  ident: 864_CR237
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0954-2
– volume: 22
  start-page: 744
  year: 2009
  ident: 864_CR131
  publication-title: Mod. Pathol.
  doi: 10.1038/modpathol.2009.43
– volume: 1
  start-page: 749283
  year: 2021
  ident: 864_CR111
  publication-title: Front. Mol. Med.
  doi: 10.3389/fmmed.2021.749283
– volume: 144
  start-page: 646
  year: 2011
  ident: 864_CR22
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 22
  start-page: 5527
  year: 2016
  ident: 864_CR102
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-0569
– volume: 15
  start-page: 563
  year: 2019
  ident: 864_CR100
  publication-title: JCO Oncol. Pract.
  doi: 10.1200/JOP.19.00357
– volume: 45
  start-page: 988
  year: 2019
  ident: 864_CR53
  publication-title: Intensive Care Med.
  doi: 10.1007/s00134-019-05650-w
– volume: 98
  start-page: e16785
  year: 2019
  ident: 864_CR231
  publication-title: Medicine
  doi: 10.1097/MD.0000000000016785
– volume: 17
  start-page: 296
  year: 2021
  ident: 864_CR128
  publication-title: Nat. Rev. Endocrinol.
  doi: 10.1038/s41574-021-00470-9
– volume: 30
  start-page: 19
  year: 2022
  ident: 864_CR74
  publication-title: Biomol. Ther.
  doi: 10.4062/biomolther.2021.047
– volume: 28
  start-page: 3411
  year: 2022
  ident: 864_CR249
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-21-4498
– volume: 14
  start-page: 667
  year: 2009
  ident: 864_CR147
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2009-0009
– volume: 17
  year: 2018
  ident: 864_CR21
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0804-2
– volume: 140
  start-page: 3079
  year: 2013
  ident: 864_CR159
  publication-title: Development
  doi: 10.1242/dev.091744
– volume: 37
  start-page: 183
  year: 2020
  ident: 864_CR212
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.12.013
– volume: 67
  start-page: 4408
  year: 2007
  ident: 864_CR97
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-4443
– volume: 17
  year: 2018
  ident: 864_CR92
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0776-2
– volume: 28
  start-page: iv41
  year: 2017
  ident: 864_CR141
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdx219
– volume: 40
  start-page: 964
  year: 2021
  ident: 864_CR120
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01539-x
– volume: 13
  start-page: 1538
  year: 2021
  ident: 864_CR244
  publication-title: Cancers
  doi: 10.3390/cancers13071538
– volume: 13
  start-page: 677
  year: 2021
  ident: 864_CR171
  publication-title: Cancer Manag. Res.
  doi: 10.2147/CMAR.S201024
– volume: 111
  start-page: 3445
  year: 2020
  ident: 864_CR188
  publication-title: Cancer Sci.
  doi: 10.1111/cas.14609
– volume: 39
  start-page: 3341
  year: 2019
  ident: 864_CR10
  publication-title: Anticancer Res.
  doi: 10.21873/anticanres.13476
– volume: 54
  start-page: 315
  year: 2022
  ident: 864_CR79
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2022.078
– volume: 168
  start-page: 960
  year: 2017
  ident: 864_CR169
  publication-title: Cell
  doi: 10.1016/j.cell.2017.02.004
– volume: 387
  start-page: 120
  year: 2022
  ident: 864_CR165
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2204619
– volume: 14
  start-page: 23
  year: 2021
  ident: 864_CR225
  publication-title: J. Hematol., Oncol.
  doi: 10.1186/s13045-021-01040-2
– volume: 2
  start-page: 257
  year: 2001
  ident: 864_CR129
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/35067005
– volume: 23
  start-page: 1698
  year: 2009
  ident: 864_CR138
  publication-title: Leukemia
  doi: 10.1038/leu.2009.111
– volume: 19
  start-page: 499
  year: 2022
  ident: 864_CR203
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-022-00639-9
– volume: 355
  start-page: 1152
  year: 2017
  ident: 864_CR175
  publication-title: Science
  doi: 10.1126/science.aam7344
– volume: 65
  start-page: 3123
  year: 2022
  ident: 864_CR185
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.1c01688
– volume: 125
  start-page: 43
  year: 2017
  ident: 864_CR5
  publication-title: Br. Med. Bull.
  doi: 10.1093/bmb/ldx045
– volume: 14
  start-page: 851
  year: 2021
  ident: 864_CR215
  publication-title: Expert Rev. Hematol.
  doi: 10.1080/17474086.2021.1969911
– volume: 18
  start-page: 1054
  year: 2004
  ident: 864_CR118
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2403355
– volume: 438
  start-page: 820
  year: 2005
  ident: 864_CR122
  publication-title: Nature
  doi: 10.1038/nature04186
– volume: 12
  start-page: 251
  year: 2020
  ident: 864_CR243
  publication-title: Breast Cancer
– volume: 9
  start-page: 329
  year: 2019
  ident: 864_CR157
  publication-title: Cancer Disco.
  doi: 10.1158/2159-8290.CD-18-1321
– volume: 21
  start-page: 2227
  year: 2015
  ident: 864_CR95
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-2791
– volume: 8
  start-page: 5
  year: 2022
  ident: 864_CR186
  publication-title: Cell Disco.
  doi: 10.1038/s41421-021-00368-w
– volume: 586
  start-page: 133
  year: 2020
  ident: 864_CR193
  publication-title: Nature
  doi: 10.1038/s41586-020-2541-0
– volume: 13
  start-page: 559
  year: 2013
  ident: 864_CR135
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3563
– volume: 73
  start-page: 1503
  year: 2013
  ident: 864_CR198
  publication-title: Drugs
  doi: 10.1007/s40265-013-0111-6
– volume: 11
  start-page: 6414
  year: 2005
  ident: 864_CR64
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-0790
– volume: 11
  year: 2013
  ident: 864_CR114
  publication-title: Cell Commun. Signal.
  doi: 10.1186/1478-811X-11-97
– volume: 381
  start-page: 2315
  year: 2019
  ident: 864_CR144
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1902328
– volume: 12
  start-page: 1443
  year: 2007
  ident: 864_CR50
  publication-title: Oncologist
  doi: 10.1634/theoncologist.12-12-1443
– volume: 44
  start-page: 2806
  year: 2008
  ident: 864_CR56
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.09.013
– volume: 7
  year: 2021
  ident: 864_CR211
  publication-title: NPJ Breast Cancer
  doi: 10.1038/s41523-021-00265-1
– volume: 51
  start-page: 37
  year: 2021
  ident: 864_CR101
  publication-title: Jpn. J. Clin. Oncol.
  doi: 10.1093/jjco/hyaa192
– volume: 4
  start-page: 815
  year: 2003
  ident: 864_CR31
  publication-title: Nat. Immunol.
  doi: 10.1038/ni0903-815
– volume: 16
  start-page: 207
  year: 2021
  ident: 864_CR253
  publication-title: Curr. Hematol. Malig. Rep.
  doi: 10.1007/s11899-021-00619-3
– volume: 17
  start-page: 318
  year: 2017
  ident: 864_CR124
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2017.8
– volume: 8
  start-page: 564601
  year: 2020
  ident: 864_CR178
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2020.564601
– volume: 37
  start-page: 530
  year: 2020
  ident: 864_CR232
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.03.006
– volume: 1877
  start-page: 188666
  year: 2022
  ident: 864_CR217
  publication-title: Biochim. Biophys. Acta Rev. Cancer
  doi: 10.1016/j.bbcan.2021.188666
– volume: 5
  start-page: 228
  year: 2020
  ident: 864_CR48
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-00313-5
– volume: 359
  start-page: 97
  year: 2018
  ident: 864_CR194
  publication-title: Science
  doi: 10.1126/science.aan4236
– volume: 15
  start-page: 7471
  year: 2009
  ident: 864_CR38
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-09-1070
– volume: 121
  start-page: 725
  year: 2019
  ident: 864_CR75
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-019-0573-8
– volume: 22
  start-page: 1276
  year: 2008
  ident: 864_CR113
  publication-title: Genes Dev.
  doi: 10.1101/gad.1653708
– volume: 81
  start-page: 1107
  year: 2021
  ident: 864_CR72
  publication-title: Drugs
  doi: 10.1007/s40265-021-01533-x
– volume: 12
  start-page: 115
  year: 2021
  ident: 864_CR163
  publication-title: Lung Cancer
– volume: 99
  start-page: 1433
  year: 2019
  ident: 864_CR108
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00029.2018
– volume: 8
  start-page: 235
  year: 2009
  ident: 864_CR123
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd2792
– volume: 30
  start-page: 1121
  year: 2019
  ident: 864_CR98
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdz131
– volume: 128
  start-page: 331
  year: 2016
  ident: 864_CR172
  publication-title: Blood
  doi: 10.1182/blood-2016-02-702761
– volume: 124
  start-page: 1757
  year: 2021
  ident: 864_CR228
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01344-7
– volume: 10
  start-page: 2019
  year: 2011
  ident: 864_CR82
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0697
– volume: 10
  start-page: 1255
  year: 2021
  ident: 864_CR32
  publication-title: Cells
  doi: 10.3390/cells10051255
– volume: 27
  start-page: 819
  year: 2022
  ident: 864_CR62
  publication-title: Molecules
  doi: 10.3390/molecules27030819
– volume: 35
  start-page: 1317
  year: 2021
  ident: 864_CR236
  publication-title: Leukemia
  doi: 10.1038/s41375-021-01123-6
– volume: 27
  start-page: 4702
  year: 2008
  ident: 864_CR65
  publication-title: Oncogene
  doi: 10.1038/onc.2008.109
– volume: 9
  start-page: 331
  year: 2009
  ident: 864_CR93
  publication-title: Expert Rev. Anticancer Ther.
  doi: 10.1586/14737140.9.3.331
– volume: 82
  start-page: 5350
  year: 2022
  ident: 864_CR78
  publication-title: Cancer Res.
  doi: 10.1158/1538-7445.AM2022-5350
– volume: 33
  start-page: 122
  year: 2012
  ident: 864_CR148
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2011.11.002
– volume: 92
  start-page: 102137
  year: 2021
  ident: 864_CR242
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2020.102137
– volume: 5
  start-page: 875
  year: 2004
  ident: 864_CR166
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/nrm1498
– volume: 99
  start-page: 1191
  year: 2014
  ident: 864_CR234
  publication-title: Haematologica
  doi: 10.3324/haematol.2013.096776
– volume: 53
  start-page: 199
  year: 2014
  ident: 864_CR184
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201307387
– volume: 87
  start-page: 4577
  year: 2021
  ident: 864_CR250
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/bcp.14889
– volume: 8
  start-page: 111
  year: 2016
  ident: 864_CR16
  publication-title: J. Innate Immun.
  doi: 10.1159/000443526
– volume: 17
  year: 2018
  ident: 864_CR24
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0782-4
– volume: 21
  start-page: 3584
  year: 2015
  ident: 864_CR187
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-0407
– volume: 71
  start-page: 209
  year: 2021
  ident: 864_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21660
– volume: 17
  start-page: 93
  year: 2017
  ident: 864_CR160
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc.2016.138
– volume: 12
  start-page: 2801
  year: 2020
  ident: 864_CR239
  publication-title: Cancers
  doi: 10.3390/cancers12102801
– volume: 78
  start-page: 549
  year: 2018
  ident: 864_CR240
  publication-title: Drugs
  doi: 10.1007/s40265-018-0884-8
– ident: 864_CR149
– volume: 8
  start-page: 1
  year: 2014
  ident: 864_CR254
  publication-title: Pharmaceuticals
  doi: 10.3390/ph8010001
– volume: 7
  start-page: 169
  year: 2007
  ident: 864_CR68
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc2088
– volume: 147
  start-page: 375
  year: 2020
  ident: 864_CR86
  publication-title: Adv. Cancer Res.
  doi: 10.1016/bs.acr.2020.04.009
– volume: 7
  start-page: 519
  year: 2013
  ident: 864_CR223
  publication-title: Drug Des. Devel. Ther.
  doi: 10.2147/DDDT.S31442
– volume: 2019
  start-page: lgz008
  year: 2019
  ident: 864_CR13
  publication-title: J. Natl Cancer Inst. Monogr.
  doi: 10.1093/jncimonographs/lgz008
– volume: 1855
  start-page: 1
  year: 2015
  ident: 864_CR219
  publication-title: Biochim. Biophys. Acta
– ident: 864_CR84
  doi: 10.1200/EDBK_159167
– volume: 12
  start-page: 755053
  year: 2022
  ident: 864_CR39
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.755053
– volume: 31
  start-page: S839
  year: 2020
  ident: 864_CR77
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.08.1610
– volume: 44
  start-page: 25
  year: 2016
  ident: 864_CR7
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.007
– volume: 9
  start-page: 800
  year: 2019
  ident: 864_CR58
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2019.00800
– volume: 13
  start-page: 905
  year: 2006
  ident: 864_CR119
  publication-title: Endocr. Relat. Cancer
  doi: 10.1677/erc.1.01221
– volume: 10
  start-page: 4233s
  year: 2004
  ident: 864_CR63
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-040005
– volume: 8
  start-page: 3980
  year: 2017
  ident: 864_CR208
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.14012
– volume: 6
  start-page: 1511
  year: 2018
  ident: 864_CR35
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0193
– volume: 44
  start-page: 34
  year: 2016
  ident: 864_CR9
  publication-title: Medicine
  doi: 10.1016/j.mpmed.2015.10.012
– volume: 10
  start-page: 4874
  year: 2021
  ident: 864_CR226
  publication-title: Cancer Med
  doi: 10.1002/cam4.4041
– volume: 25
  start-page: 3759
  year: 2019
  ident: 864_CR176
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0968
– volume: 19
  start-page: 327
  year: 2013
  ident: 864_CR154
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-2087
– volume: 8
  start-page: 373
  year: 2015
  ident: 864_CR230
  publication-title: Ther. Adv. Gastroenterol.
  doi: 10.1177/1756283X15592586
– volume: 78
  start-page: 1947
  year: 2018
  ident: 864_CR200
  publication-title: Drugs
  doi: 10.1007/s40265-018-1028-x
– volume: 7
  start-page: 122
  year: 2015
  ident: 864_CR241
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758834014566428
– volume: 62
  start-page: 1556
  year: 2016
  ident: 864_CR15
  publication-title: Clin. Chem.
  doi: 10.1373/clinchem.2015.247882
– volume: 17
  year: 2018
  ident: 864_CR96
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0810-4
– volume: 7
  start-page: 723
  year: 2016
  ident: 864_CR204
  publication-title: J. Adv. Pract. Oncol.
– volume: 19
  start-page: 1933
  year: 2013
  ident: 864_CR155
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-0284
– volume: 7
  start-page: 1074
  year: 2021
  ident: 864_CR227
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2021.07.003
– volume: 59
  start-page: 13764
  year: 2020
  ident: 864_CR27
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201914525
– volume: 17
  start-page: 77
  year: 2010
  ident: 864_CR104
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2009.11.022
– volume: 14
  start-page: 6618
  year: 2008
  ident: 864_CR94
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1018
– volume: 15
  start-page: 79
  year: 2022
  ident: 864_CR214
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-022-01299-z
– volume: 15
  start-page: 2207
  year: 2009
  ident: 864_CR103
  publication-title: Clin. Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1306
– volume: 8
  start-page: 237
  year: 2017
  ident: 864_CR142
  publication-title: Ther. Adv. Hematol.
  doi: 10.1177/2040620717719851
– volume: 70
  start-page: 1059
  year: 2010
  ident: 864_CR89
  publication-title: Drugs
  doi: 10.2165/11205090-000000000-00000
– volume: 13
  start-page: 175883592199297
  year: 2021
  ident: 864_CR99
  publication-title: Ther. Adv. Med. Oncol.
  doi: 10.1177/1758835921992976
– volume: 15
  start-page: 731
  year: 2018
  ident: 864_CR106
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-018-0113-0
– volume: 25
  start-page: 2949
  year: 2019
  ident: 864_CR210
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-3003
– volume: 8
  start-page: 935
  year: 2002
  ident: 864_CR19
  publication-title: Clin. Cancer Res.
– volume: 8
  start-page: 109
  year: 2017
  ident: 864_CR71
  publication-title: Lung Cancer
– volume: 30
  start-page: 125
  year: 2018
  ident: 864_CR168
  publication-title: Curr. Opin. Oncol.
  doi: 10.1097/CCO.0000000000000426
– volume: 40
  start-page: 1155
  year: 2022
  ident: 864_CR246
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.02742
– volume: 71
  start-page: 1412
  year: 2022
  ident: 864_CR191
  publication-title: Gut
  doi: 10.1136/gutjnl-2021-326264
– volume: 33
  start-page: 131
  year: 2011
  ident: 864_CR233
  publication-title: Rev. Bras. Hematol. Hemoter.
  doi: 10.5581/1516-8484.20110034
– volume: 125
  start-page: 155
  year: 2021
  ident: 864_CR4
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-021-01319-8
SSID ssj0025474
Score 2.6688774
SecondaryResourceType review_article
Snippet Since the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small...
SourceID pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1670
SubjectTerms 631/67/1059/602
692/699/67/1059/602
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer therapies
Chemotherapy
Drug development
Drug resistance
Drug Resistance, Neoplasm
Humans
Medical Biochemistry
Molecular Medicine
Molecular Targeted Therapy
Monoclonal antibodies
Mutation
Neoplasms - drug therapy
Neoplasms - genetics
Precision Medicine
Review
Review Article
Signal transduction
Stem Cells
Therapeutic targets
Tumor cells
SummonAdditionalLinks – databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEB50BfEivq2uUkG8aLBN0qQ9yuIiwnpS8FaSJkVBu-LuHvbfO0kfsr7Ac6Y0nUkmXzoz3wCcJoWOtYokMdxYwrNUEGUzSRCZSiuo1EniipNHd-Lmgd8-Jo9LQNtaGJ-07yktvZtus8MuJzGl0qXLUuJQOCdsGVYcdbtb1QMx6C5ZCZe8KY6JWPrDc4sH0DdU-T058kuE1B88ww1YbxBjeFXPcROWbLUF21c4_fHrPDwLfQ6n_zm-BaujJlS-DWzUNr4N62xva8K62GoeIlANUaPOAxYWx9tk8x24H17fD25I0yGBFIi0poQznpiojDImilLqjJaMGQQReO0zNk4VVzqlWiNGEbYQUsUIVyJhU8uNlFqzXehV48ruQ-gajScR-jrHFVwak1rFHbtUTGMhFFUBxK3W8qJhD3dNLF5yH8VmaV5rOkdN517TOQvgvHvmrebO-FO63xojb_bRJEdwFWecsYQHcNIN4w5wYQ1V2fHMyVAX7EUcGcBebbvudXg8U1c7G4BcsGon4Ni1F0eq5yfPso2eCaFLFsBFa__Paf3-FQf_Ez-ENerWps8O7ENv-j6zR4hypvrYL-sPHED03w
  priority: 102
  providerName: Springer Nature
Title Molecular targeted therapy for anticancer treatment
URI https://link.springer.com/article/10.1038/s12276-022-00864-3
https://www.ncbi.nlm.nih.gov/pubmed/36224343
https://www.proquest.com/docview/2731943354
https://www.proquest.com/docview/2724584226
https://pubmed.ncbi.nlm.nih.gov/PMC9636149
Volume 54
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Ra9swED7WFkZfytZuq7sueDD2sonakizZTyMLLSWQMrYO8mYkS6GFzWmb9KH_vneynJCV9ckgydi6k-6-053uAD4Vjc2tyTRz0nkmq1Ix4yvNEJlqr7i2RUGXkycX6vy3HE-LaTxwW8Swyl4mBkHt5g2dkZ-gmkV7W4hCfru5ZVQ1iryrsYTGFuxQ6jIK6dLTtcFVyJCFOUeIwQTqrXhpJhPlyQIbNYXfckaoXjKxqZieoM2nQZP_eE6DQjp7BXsRSabDjvWv4YVv9-Fg2KIV_fch_ZyG2M5waL4PLyfRhX4AYtIXxE27KHDv0u4S1kOKADZFSpNkbDz290Hob-Dy7PRydM5i5QTWIAJbMilk4bJZVgnVzLSt-EwIh-ACzUHn89JIY0tuLWIX5RulTY4wJlO-9NJpba14C9vtvPWHkFIB8iJDGUg5hGfOld5IyjqV81wpw00CeU-1uolZxam4xZ86eLdFWXeUrpHSdaB0LRL4snrnpsup8ezo454Zddxfi3q9GhL4uOrGnUHuDtP6-T2N4eQERuYn8K7j3epzqLY53alNQG9wdTWAsm5v9rTXVyH7NkoshDRVAl97_q9_6_-zOHp-Fu9hl9NaDFGCx7C9vLv3HxDtLO0gLOkB7AyH419jfH4_vfjxE1tHajQIJwiPAET98w
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEGx8BAYYCXgBa4nt2OkDQgM2dWytECrS3iw7dgUSpIN2Qv2j-B-5y9dUJva219pJmrvz3e9yXwDP89Jn3qWGBxUiV8NCcxeHhiMyNVEL4_OcipPHEz36oj6e5Ccb8KerhaG0yk4n1oo6zEv6Rr6LZhb9bSlz9fb0J6epURRd7UZoNGJxFFe_0WVbvDn8gPx9IcTB_vT9iLdTBXiJ6GTJlVR5SGfoyetyZvxQzKQMaHjRVQoxK5xyvhDeo13XsdTGZWjiUx2LqIIx3ku87TXYVBI9mQFsvtuffPrce3i5qts-Z4hpuERD2VbppLLYXeCPhvJ9BSc3QnG5bgkvwNuLWZr_hGprC3hwG2610JXtNbJ2BzZitQXbexW67T9W7CWrk0nrr_RbcH3cxuy3QY67CbysSTuPgTVVXyuGiJkha0kVlxHXu6z3uzC9CqLeg0E1r-IDYDTxPE9R6VLT4lkIRXSK2lxlItPaCZdA1lHNlm0bc5qm8d3W4XRZ2IbSFilta0pbmcCr_prTponHpbt3OmbY9kAv7Ln4JfCsX8ajSPEVV8X5Ge0RFHVG5idwv-Fd_zjECYKKeBMwa1ztN1Cb7_WV6tvXut03qkjEUMMEXnf8P_9b_3-Lh5e_xVO4MZqOj-3x4eToEdwUJJd1iuIODJa_zuJjhFpL_6QVcAb2io_UXwRwNec
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFSKVHFB0PIIFDAScAFrE9uJsweEKsqqpWzFoUh7s-zYEZVKtrBbof20_l1nnGRXS0VvvcbOa97jeQG8ySuXOZtq7pUPXA3Lgtsw1BwtUx0KoV2eU3Hy-Lg4-KG-TvLJBlz2tTCUVtnLxCio_bSiM_IBqln0t6XM1aDu0iK-748-nf_mNEGKIq39OI2WRI7C4i-6b7OPh_uI67dCjL6cfD7g3YQBXqGlMudKqtynNXr1RVVrNxS1lB6VMLpNPmSlVdaVwjnU8UWoCm0zVPdpEcqgvNbOSXzsHbirZZ4Ri-nJytfLVWwAnaF1wyWqzK5eJ5XlYIYXNWX-Ck4OheJyXSdeM3Sv52v-E7SNunD0AO53Rizba6nuIWyEZht29hp04H8t2DsW00rjef02bI276P0OyHE_i5e1CejBs7b-a8HQdmaIZBLKVcD1Pv_9EZzcBkgfw2YzbcJTYDT7PE9R_FL74tr7MlhFDa8ykRWFFTaBrIeaqbqG5jRX48zEwLosTQtpg5A2EdJGJvB-ec95287jxt27PTJMx9ozsyLEBF4vl5EpKdJimzC9oD2C4s-I_ASetLhbvg4tBkHlvAnoNawuN1DD7_WV5vRnbPyNwhKtqWECH3r8rz7r_3_x7Oa_eAVbyEjm2-Hx0XO4J4gsY67iLmzO_1yEF2hzzd3LSN0MzC1z0xVMWTi3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+targeted+therapy+for+anticancer+treatment&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Min%2C+Hye-Young&rft.au=Lee%2C+Ho-Young&rft.date=2022-10-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=1226-3613&rft.eissn=2092-6413&rft.volume=54&rft.issue=10&rft.spage=1670&rft.epage=1694&rft_id=info:doi/10.1038%2Fs12276-022-00864-3&rft_id=info%3Apmid%2F36224343&rft.externalDocID=PMC9636149
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon